Microwave-assisted synthesis of N-heterocycles in medicinal chemistry by Garella, Davide et al.
	  	  	  	  
	  
	  MedChemComm,	  4,10,	  2013,	  DOI:	  10.1039/c3md00152k	  
[Davide	  Garella,	  Emily	  Borretto,	  Antonella	  Di	  Stilo,	  Katia	  Martina,	  Giancarlo	  
Cravotto,	  Pedro	  Cintas,	  4,	  RSCPublishing,	  2013,	  pagg.1323-­‐1343]	  
The	  definitive	  version	  is	  available	  at:	  



















Microwave-­‐assisted	  synthesis	  of	  N-­‐heterocycles	  in	  
medicinal	  chemistry	  	   Davide	  Garella,a	  Emily	  Borretto,	  a	  Antonella	  Di	  Stilo,	  a	  Katia	  Martina,	  a	  Giancarlo	  Cravotto*a	  and	  Pedro	  Cintasb	  	  The	   syntheses	   of	   almost	   all	   N-­‐heterocycles	   have	   now	   been	   successfully	   performed	   under	  microwave	  irradiation	  and	  have	  provided	  significant	  improvements	  in	  the	  reaction	  time	  and	  efficiency.	  The	  peculiar	  properties	  of	  dielectric	  heating	  give	  it	  the	  ability	  to	  strongly	  promote	  cyclocondensation,	   cycloaddition	   and	   selective	   N-­‐heterocycle	   functionalisation	   and	   it	   has,	  therefore,	   very	   much	   caught	   the	   attention	   of	   the	   medicinal	   chemistry	   community.	   In	   this	  work,	   we	   present	   an	   overview	   of	   recent	   literature	   and	   technical	   advances	   in	   this	   research	  field	  with	  the	  aim	  of	  providing	  insight	  into	  the	  applications	  of	  microwave-­‐assisted	  synthesis	  in	  the	  preparation	  of	  the	  main	  drug	  categories	  that	  contain	  N-­‐heterocycle	  scaffolds.	  	  
1	  Introduction	  Microwave-­‐assisted	  organic	  synthesis	  in	  specially	  made	  equipment	  has	  grown	  into	  a	  mature	  technique	   that	   has	   been	   widely	   applied	   in	   the	   drug	   discovery	   field,	   thanks	   to	   enhanced	  reaction	  rates,	  high	  yields,	   improved	  purity	  and	  greener	  reaction	  conditions.1	  The	  reader	   is	  referred	  to	  a	  series	  of	  recent	  general	  reviews2–5	  and	  monographs6,7	  for	  in-­‐depth	  coverage	  of	  these	   subjects.	   Although	   readers	   are	   likely	   to	   be	   acquainted	   with	   the	   great	   potential	   of	  dielectric	  heating,	  the	  advantages	  and	  disadvantages	  of	  a	  particular	  device	  or	  the	  conditions	  needed	   to	  maximize	   the	  efficiency	  and	   functionality	  are	  often	  overlooked.	   In	   recent	  years	  a	  great	  deal	  of	  attention	  has	  been	  paid	   to	   the	  application	  of	  microwaves	  (MW)	  to	  heterocycle	  synthesis.8?13	  Ever	  since	  Van	  Noorden's	  report	  in	  2008	  entitled	  “Microwaving	  myths”,14	  in	  which	  several	  experts	  described	  the	  current	  status	  of	  MW-­‐assisted	  chemistry,	  was	  published,	  new	  technological	  advances	  have	  been	  made	  that	  have	  broadened	  the	  applications	  of	  this	  type	  of	   irradiation	   in	   synthetic	   medicinal	   chemistry.	   In	   this	   same	   reference	   J.	   Moseley	   (Astra	  Zeneca)	  is	  quoted	  as	  saying:	  ?virtually	  all	  new	  compounds	  now	  have	  their	  first	  synthesis	  in	  a	  microwave?	   and	   this	   fact	   has	   acquired	   even	  more	   relevance	   four	   years	   on.	   One-­‐pot,	  MW-­‐assisted	  multi-­‐component	  reactions	  receive	  a	  great	  deal	  of	  attention	  because	  of	  their	  ability	  to	  efficiently	   give	   access	   to	   complex	   heterocyclic	   structures.	   Eloquent	   examples	   are	   the	   Ugi	  reaction	  and	  several	  heterocycle-­‐cyclizations.15	  The	   latest	   generation	   of	   lab	   scale	   reactors	   offer	   high	   power	   density	   (1.5	   kW	   L-1),	   high	  temperature	  (up	  to	  300°C),	  high	  pressure	  (up	  to	  200	  bar	  with	  gas	  inlets),	  multi-­‐sample	  racks	  and	  extremely	  fast	  cooling	  when	  the	  reaction	  is	  complete.16	  Impressive	  advances	  have	  been	  achieved	   on	   the	   “kilolab”	   scale,	   as	   recently	   reported	   by	   Morschh	  ̈auser	   et	   al.	   (Clariant),17	  thanks	  to	  a	  continuous	  flow	  MW-­‐system	  that	  is	  based	  on	  a	  trans-­‐	  mission	  line	  short-­‐circuited	  waveguide	   reactor	   (2.45	   GHz,	   max	   power	   6	   kW)	   which	   combines	   the	   benefits	   of	   existing	  mono-­‐	  and	  multimode	  technologies.	  The	  present	  review	  will	  focus	  entirely	  on	  the	  pivotal	  role	  played	  by	  MW	  in	  the	  cyclization	  of	  N-­‐heterocycles	  in	  the	  drug	  discovery	  field.	  To	  this	  end,	  we	  have	   brought	   together	   the	   expertise	   of	   synthetic	   organic	   chemists	   and	  medicinal	   chemists	  with	  the	  aim	  of	  highlighting	  relevant	  operative	  information	  on	  a	  target	  N-­‐heterocycle	  and	  its	  biological/pharmacological	   activity.	   60	   different	   cyclizations	   are	   herein	   reported.	   Besides	  reactions	   performed	   in	   professional	   MW	   reactors,	   some	   examples	   refer	   to	   cyclization	  performed	  in	  poorly	  standardized	  apparatus	  (domestic	  MW	  ovens)	   in	  which	  the	  monitoring	  of	   the	  temperature	  was	  generally	   impossible.	   Instead	  of	  rejecting	  relevant	   findings	   in	  which	  cyclizations	   were	   performed	   in	   a	   domestic	   oven,	   these	   references	   were	   supported	   with	  additional	  reports	  that	  refer	  to	  the	  same	  selected	  cyclization	  but	  performed	  in	  a	  professional	  MW	  oven.	  
	  




All	  products	  were	  tested	  for	  in	  vitro	  antimicrobial	  activity	  and	  interesting	  results	  were	  found	  in	  the	  presence	  of	  –Cl,	  –F,	  –NO2	  and	  –OH	  substituent	  groups.	  The	   determination	   of	   the	   Mycobacterium	   tuberculosis	   (MTB)	   genome	   sequence	   provided	  information	   which	   was	   crucial	   for	   the	   design	   of	   new	   drugs	   made	   to	   target	   this	   pathogen.	  Promising	  data	  have	  recently	  suggested	  that	  targeting	  MTB	  lipid	  metabolism	  pathways	  might	  provide	  an	  excellent	   route	   for	  attenuating	  or	  killing	   the	  bacterium.	  McLean	  and	  co-­‐workers	  have	  demonstrated	  that	  some	  azole	  compounds	  are	  potent	  inhibitors	  of	  Mycobacterium	  bovis	  and	  Mycobacterium	  smegmatis	  (two	  mycobacterial	  species	  which	  closely	  resemble	  MTB)	  cell	  growth.21	  By	  using	  these	  results,	  Botta	  et	  al.	  decided	  to	  more	  closely	  focus	  their	  attention	  on	  novel	   azole	   analogues	   with	   polycyclic	   structures	   which	   resemble	   typical	   antifungal/anti-­‐	  bacterial	   azole	   drugs.22	   An	   enantiopure	   form	   of	   arylpropargylamide	   was	   converted	   into	  1,2,3-­‐triazole	  via	  a	  MW-­‐assisted	  click	  reaction	  in	  the	  presence	  of	  CuSO4	  and	  sodium	  ascorbate.	  The	  N-­‐acetyl	  group	  was	  removed	  in	  the	  presence	  of	  3	  N	  HCl	  by	  heating	  in	  an	  oil	  bath	  at	  100°C.	  The	  products	  obtained	  (3)	  were	  used	  in	  the	  next	  step	  without	  further	  purification	  (Scheme	  3).	  The	  introduction	  of	  the	  imidazole	  ring	  from	  a	  primary	  amine	  was	  performed	  by	  a	  one-­‐pot	  MW	  procedure	  at	  80?C	  (H3PO4,	  para-­‐formaldehyde,	  glyoxal	  aqueous	  solution	  (40%),	  NH4Cl,	  H2O/	  dioxane,	  10	  min).	  The	  products	  obtained	  were	  tested	  for	  their	  inhibitory	  activity	  toward	  MTB.	  The	  influence	  of	  different	  substituents	  on	  the	  phenyl	  rings	  and	  on	  the	  chirality	  of	  the	  synthesized	  products	  was	  studied.	  Although	  most	  of	   the	  compounds	  showed	  moderate	  activity,	   the	  bromo	  derivatives	  (4)	   showed	  excellent	  MIC	  values	  and	   the	   (R)-­‐enantiomers,	   in	  particular,	  demonstrated	  very	  promising	  antimycobacterial	  activity	  and	  biological	  profiles	  that	  are	  similar	  to	  econazole	  and	  better	   than	   clo-­‐	   trimazole.	  These	   results	   confirmed	  higher	   activity	  of	   enantiomerically	  pure	  compounds	   that	   is	   due	   to	   the	   specific	   interactions	   single	   enantiomers	   have	   with	   chiral	  biological	  systems.	  Several	   antimicrobial	   and	  antitubercular	  drugs	  bear	  pyridine	  or	  quinolone	  moieties.	  Manna	  and	  Agrawal	  have	  designed	  numerous	  benzofuranpyrazoline	  frameworks	  that	  contain	  both	  N-­‐heterocycle	   rings	  and	  have	  evaluated	   their	   in	  vitro	  and	   in	  vivo	  antitubercular	  activity.23	   In	  the	  first	  synthetic	  step,	  the	  chalcone	  was	  synthesized	  from	  2-­‐acetyl	  benzofuran	  using	  various	  aromatic	  aldehydes	  and	  MW	  irradiation	  (Synthos-­‐3000,	  Anton	  Paar)	  for	  10	  min	  at	  130?C	  and	  10	   bar	   (EtOH,	   10%	   KOH)	   (Scheme	   4).	   The	   product	   was	   further	   treated	  with	   two	   different	  hydrazides	   (isonicotinic	   acid	   hydrazide	   and	   nalidixic	   acid	   hydrazide)	   to	   give	   the	   final	  compounds	  3-­‐benzofuran-­‐5-­‐aryl-­‐1-­‐pyr-­‐	  azolylcarbonyl-­‐4-­‐oxo-­‐naphthyridins	  5	  (12	  min,	  110?C/10	   bar)	   and	   3-­‐benzofuran-­‐5-­‐aryl-­‐1-­‐pyrazolyl-­‐pyridylmethanones	   6	   (14	   min,	   120?C/10	  bar).	  MW	  irradiation	  was	  employed	   in	  the	   final	  step	  of	   the	  reaction	  and	  provided	  rapid	  and	  efficient	  diazole	  cyclisation.	  
	  	  The	   in	   vitro	   antitubercular	   activity	   was	   tested	   by	   measuring	   the	   growth	   of	   MTB	   in	   the	  Lowensteine	   Jensen	   medium.	   The	   naphthyridin	   ring	   is	   more	   favourable	   than	   the	   pyr-­‐	  idinylcarbonyl	   ring	   for	   giving	  potent	   activity.	  The	  antitubercular	   activity	  may	  be	  due	   to	   the	  formation	   of	   the	   free	   isonicotinoyl-­‐NAD	   complex,	   which	   might	   be	   responsible	   for	   the	  inhibition	  of	  cell	  wall	  biosynthesis	   in	  the	  mycobacterium.	  The	  highest	  activity	  was	  observed	  for	   the	   (o)-­‐NO2	   substituent	   in	   compounds	   5	   and	   for	   the	   (o)-­‐COOH	   substituent	   in	   6.	   The	  carboxylic	  group	  contained	   in	  compound	  6	  seems	   to	  actively	  contribute	   to	   the	   formation	  of	  this	  complex	  and	  therefore	  was	  particularly	  active	  against	  multidrug-­‐resistant	  MTB.	  Analogously,	  with	  the	  aim	  of	  exploring	  the	  synergic	  antitubercular	  activity	  of	  two	  structures	  in	   the	   same	   framework,	   Alegaon	   et	   al.	   considered	   the	   functionalisation	   of	   imidazo[2,1-­‐b]-­‐	  [1,3,4]-­‐thiadiazole	  with	  thiazolidine-­‐2,4-­‐diones	  and	  rhodanines,24	  and	  these	  two	  derivatives	  showed	  very	  promising	  pharmacological	  activity.	  The	  core	  structure	  was	  synthesised	  under	  MW	  irradiation;	  previously	  prepared	  5-­‐(trifluoromethyl)-­‐	  1,3,4-­‐thiadiazol-­‐2-­‐amine	  and	  multi-­‐substituted	  α-­‐haloaryl	  ketones	  were	   irradiated	  at	  600	  W	  for	  10?15	  min	  (Scheme	  5).	  The	  2-­‐(trifluoromethyl)-­‐6-­‐arylimidazo[2,1-­‐b][1,3,4]-­‐thiadiazoles	  were	   formylated	   at	   position	   5	   via	  the	   Vilsmeier?Haack	   reaction	   and	   then	   subjected	   to	   Knoevenagel	   condensation	  which	   gave	  the	   desired	   products.	   All	   the	   reactions	   were	   carried	   out	   under	   both	   conventional	   and	  dielectric	  heating	  and	  results	  showed	  that	  MW	  irradiation	  dramatically	  cut	  down	  the	  reaction	  time	  to	  a	  few	  minutes.	  A	  weak	  antitubercular	  effect	  was	  observed	  with	  the	  thiazolidinedione	  moiety,	  while	  an	  enhanced	  activity	  was	  detected	  when	  the	  structure	  included	  rhodanine	  and	  even	  more	  so	  with	  rhodanine-­‐3-­‐acetic	  acid.	  
	  	  Another	   combination	   of	   two	   active	   heterocycles	  was	   reported	   by	   Dubey	   and	   coworkers,25	  who	  described	  the	  MW-­‐assisted	  synthesis	  of	  some	  azetidinone	  derivatives	  that	  possess	  a	  ben-­‐	  zotriazole	  moiety.	  The	  benzotriazole	  was	  first	  alkylated	  with	  1-­‐	  bromo-­‐3-­‐chloropropane	  and	  then	  rapidly	  converted	  to	  the	  hydrazine	  derivative	  under	  MW	  irradiation	  (3	  min	  in	  a	  domestic	  MW	  oven)	  (Scheme	  6).	  After	   chromatographic	   purification,	   the	   product	   was	   reacted	   with	   different	   benzaldehyde	  derivatives	  in	  the	  presence	  of	  a	  catalytic	  amount	  of	  glacial	  acetic	  acid	  to	  give	  the	  benzaldehy-­‐	  dehydrazone	  derivative.	  The	  desired	  azetidinone	  derivatives	  of	  benzotriazole	  were	  eventually	  obtained	  via	  a	  reaction	  with	  ClCH2COCl	  in	  the	  presence	  of	  TEA.	  The	  extremely	  fast	  procedure	  (just	  a	  few	  minutes)	  gave	  yields	  that	  were	  20%	  higher	  than	  that	  of	  the	  conventional	  method.	  Electron	  withdrawing	   groups	   on	   the	  Ar	  moiety	   generally	   provided	  higher	   antibacterial	   and	  antitubercular	   activity,	   while	   a	   marked	   antifungal	   activity	   was	   caused	   by	   the	   presence	   of	  electron	  donating	  substituents.	  
	  	  1,3,4-­‐Oxadiazoles	   are	   considered	   to	   be	   an	   important	   class	   of	   heterocycles	   and	   are	   the	   core	  structure	   in	   many	   bioactive	   compounds.26	   In	   particular	   2,5-­‐unsymmetrical	   disubstituted	  derivatives	  have	  considerable	  biological	  relevance,27	  however,	  the	  syntheses	  of	  these	  spread	  heterocycles	  are	  anything	  but	  trivial.	  Fortunately,	  significant	  improvements	  in	  reaction	  rates	  and	  yields	  can	  be	  achieved	  under	  MW	  irradiation.	  By	  using	  one	  of	   their	  previous	  work	  as	  a	  base,28	  Shinde	  et	  al.	  proposed	  a	  new	  synthetic	  method	  for	  2,5-­‐disubstituted	  1,3,4-­‐oxadiazoles	  under	  MW	   conditions	   (MicroSYNTH	  MW	   labstation)	   in	   the	   presence	   of	   sodium	   bisulfite.29	  The	   MW-­‐assisted	   reaction	   was	   carried	   out	   in	   ethanol	   by	   mixing	   the	   hydrazide	   and	   the	  aromatic	   aldehyde	   using	   sodium	   bisulphite	   as	   a	   catalyst	   (yield	   95%	   in	   10–15	  min,	   100°C).	  Under	  conventional	  heating,	  complete	  cyclisation	  required	  at	  least	  9	  hours	  (Scheme	  7).	  All	  the	  products	   were	   tested	   for	   their	   in	   vitro	   antifungal	   activity.	   It	   was	   observed	   that	  functionalisation	  on	  the	  piperidine	  nitrogen	  and	  position	  5	  of	  the	  oxadiazole	  may	  dramatically	  change	  the	  activity.	  Compounds	  with	  a	  methyl	  sulphone	  group	  on	  the	  piperidine	  nitrogen	  and	  a	   Cl	   group	   on	   the	   phenyl	   moiety	   showed	   the	   same	   level	   of	   activity	   as	   miconazole	   against	  Fusariumoxysporum	  and	  Candida	  albicans.	  Replacing	  the	  Cl	  group	  with	  a	  hydroxyl	  group	  did	  
not	   affect	   the	   activity	   which	   was	   comparable	   with	   micona-­‐	   zole	   against	   Candida	   albicans,	  Aspergillus	   flavus,	   and	   Aspergillus	   niger,	   and	   equipotent	   with	   miconazole	   against	  Fusariumoxysporum.	   Of	   all	   the	   compounds	   tested,	   the	   sulfonyl	   group	   in	   R1	   and	   Cl	   or	   OH	  groups	   in	   R2	   were	   the	   most	   active	   against	   the	   tested	   organisms.	   They	   can	   certainly	   be	  considered	   important	   pharmacophores	   for	   the	   design	   and	   development	   of	   new	   antifungal	  agents.	  
	  	  Xu	   and	   co-­‐workers	   have	   recently	   synthesised	   1,3,4-­‐oxadiazoles	   containing	   the	   azulene	  moiety.	   The	   solvent-­‐less	   reaction	  mixture	   containing	   the	   azulenehydrazide,	   an	   appropriate	  carboxylic	   acid	   and	   a	   few	   drops	   of	   POCl3	   was	   irradiated	   under	   MW	   conditions	   (360	   W)	  (Scheme	  8).30	  
	  	  The	  reactions	  proceeded	  slowly	  under	  reflux	  conditions	  (only	  10–20%	  yields),	  whereas	  MW	  proved	   itself	   to	  be	  an	  excellent	   technique	   for	   the	  rapid,	   single	  step	  synthesis	  of	   the	  azulene	  moiety	   containing	   2,5-­‐disubstituted-­‐1,3,4-­‐oxadiazoles.	   Moreover,	   the	   intermediate	   can	   be	  considered	   an	   interesting	   synthon	   for	   the	   preparation	   of	   a	   variety	   of	   heterocycle-­‐fused	  azulenes.	  All	   the	  products	  obtained	  were	  tested	   for	   their	  antifungal	  activity	  and	  the	  best	  results	  were	  obtained	  with	  the	  p-­‐chlorophenyl	  substituent.	  The	  compounds	  with	  substituents	  (i.e.	  –C6H5,	  4-­‐MeC6H4	   and	  4-­‐Br-­‐C6H4)	   showed	   enhanced	   activity	   against	   the	   fungus	  Aspergillus	   flatus	   and	  moderate	   activity	   against	  Penicillium,	  while	   other	   compounds	  with	   substituents	   (i.e.	   4-­‐OHC	  C6H4,	  2-­‐OHC	  C6H4,	  –C	  C6H5CH]CH2,	  4-­‐MeC	  C6H5CH]CH2)	  showed	  moderate	  activity	  against	  the	  fungi	  Penicillium	  and	  Trichophyton.	  In	   the	   search	   for	   stronger	   antibacterial	   activity,	  Ali	   et	   al.	   incorporated	  2-­‐aminothiazole	   and	  azetidinone	  into	  a	  single	  molecular	  framework.31	  The	  conventional	  heating	  and	  MW-­‐assisted	  protocols	  (domestic	  MW	  oven)	  were	  compared.	  2-­‐Aminothiazole	  was	  reacted	  with	  a	  suitable	  aromatic	  aldehyde	  to	  rapidly	  achieve	  the	  respective	  imines	  (yield:	  MW	  85–95%,	  oil	  bath	  70–75%).	   These	   Schiff	   bases	   were	   then	   irradiated	   (1–2	   min,	   400	   W)	   in	   the	   presence	   of	  phenylacetyl	   chloride	  under	  basic	  conditions	   (TEA)	   to	  afford	   the	  azetidinones	  12	  (MW:	  85–95%;	   oil	   bath:	   60–65%)	   (Scheme	   9).	   It	   is	   important	   to	   highlight	   the	   fact	   that	   only	   a	   few	  minutes	   of	   MW	   irradiation	   were	   necessary	   to	   obtain	   the	   desired	   products	   in	   high	   yields,	  whereas	  even	  hours	  of	  conventional	  heating	  could	  not	  give	  the	  same	  results.	  
	  	  Some	  of	  the	  synthesised	  compounds	  that	  contain	  more	  than	  one	  antibacterial	  pharmacophore	  site	   showed	   good	   antibacterial	   properties.	   Moreover,	   the	   β-­‐lactam	   derivatives	   provide	   an	  interesting	   scaffold	   for	   structure–activity	   relationship	   studies	   (SAR).	   The	   modification	   of	  substituents	  and	   the	  O/N/S	  atoms	  of	   the	  pharmacophore	  groups	  had	  a	   favourable	  effect	  on	  the	  antiviral	  power	  and	  selectivity.	  Perumal	  et	  al.	  proposed	  syntheses	  of	  quinoline	  and	  bis(in-­‐	  dolyl)methanes	  via	  metal-­‐catalysed	  coupling	  cyclisation	  with	  the	  aim	  of	  investigating	  new	  synthetic	  strategies.32	  The	  reac-­‐	  tions	  between	  20	  -­‐aminoacetophenone	   and	   phenylacetylene	   in	   the	   presence	   of	   Zn(OTf)2	   (1	  mol%)	   as	   the	   catalyst	   were	   carried	   out	   under	   MW	   irradiation	   (450	   W	   for	   10	   min,	   in	   a	  domestic	  MW	  oven).	  All	   the	   reagents	  were	  stirred	   for	  5	  min	  and	   then	   transferred	   to	  a	   tube	  inserted	  in	  an	  alumina	  bath	  (100	  g,	  60	  G245,	  Fischer	  scientific	  bath).	  The	  proposed	  cyclisation	  mechanism	  is	  depicted	  in	  Scheme	  10.	  	  	   The	   catalyst	   coordinates	   the	   carbonyl	   group	  allowing	   the	   terminal	   alkyne	   nucleophilic	   attack	   to	  form	   intermediate	   I,	   which	   undergoes	   a	   Meyer-­‐Schuster	   rearrangement	   to	   form	   the	   corresponding	  allenol	   intermediate	   II,	   and	   then	   20-­‐aminochalcone	  III.	   The	   cyclocondensation	   of	   tautomer	   III	   leads	   to	  the	   elimination	   of	   water	   to	   form	   2,4-­‐disubstituted	  quinoline	  13.	  The	  same	  reaction	  conditions	  were	  employed	  for	  the	  synthesis	   of	   bis(indolyl)methanes	   from	   2-­‐phenylindole	   and	   a	   series	   of	   aldehydes.	   Both	  reactions	   were	   carried	   out	   under	   MW	   irradiation	  with	   low	   catalyst	   loading	   and	   afforded	   pure	   prod-­‐	  ucts.	   All	   products	   were	   screened	   for	   in	   vitro	   antibacterial	   and	   antifungal	   activity	   and	   the	  results	  showed	  that	  all	  compounds	  were	  active	  with	  comparable	  efficacy	  to	  reference	  drugs.	  Most	  of	  the	  bis(indolyl)methanes	  showed	  high	  antioxidant	  activity.	  Quinolinone	   synthesis	   has	   been	  widely	   described	   in	   the	   literature.	   In	   fact,	   Azas	   et	   al.	   have	  reported	  a	  new	  protocol	  that	  involves	  a	  two-­‐step	  MW	  procedure.33	  In	  the	  first	  step,	  the	  Mel-­‐	  drum's	   acid	   intermediates	  were	   prepared	   and	   the	   conventional	   conditions	  were	   compared	  with	  MW	  irradiation	  (Scheme	  11).	  
	  
	  The	   derivatives	   obtained	   were	   converted	  into	   the	   respective	   bent	   or	   linear	   tricyclic	  quinolinones,	   depending	   on	   the	   starting	  heterocycle	   (Scheme	   12).	   This	   step	   was	  further	  optimised	  by	  the	  use	  of	  ionic	  liquids	  (BMImPF6)	   as	   solvents.	   The	   reaction	  proceeded	   to	   completion	   in	   only	   3	  minutes	  at	   200?C	   under	   MW	   irradiation	   (mono-­‐mode	  cavity	  Explorer	  CEM	  MW	  Synthesizer).	  The	   ionic	   liquid	  was	   recycled	   after	   product	  precipitation.	  Curiously,	   biological	   tests	   showed	   that	   the	  Meldrum's	  acid	  derivatives	  were	  more	  active	  and	  less	  toxic	  than	  the	  corresponding	  cyclised	  compounds.	   None	   of	   the	   cyclised	   products	   showed	   any	   antimalarial,	   antileishmanial	   or	  antimicrobial	  activity.	  Thiodiazole	   and	   triazole	   derivatives	   bearing	   fluorinated	   quinolone	   were	   synthesized	   by	  Shelke	  et	  al.34	  under	  conventional	  conditions	  as	  well	  as	  under	  ultrasound	  (US)	  and	  dielectric	  heating.	   In	   the	   first	   reaction	   step,	   the	   thiosemicarbazides,	   used	   as	   starting	  materials,	   were	  prepared	   following	   a	   conventional	   procedure	   in	   ethanol	   under	   reflux	   conditions	   (60	  min).	  This	  intermediate	  underwent	  rapid	  internal	  cyclisation,	  affording	  azoles	  in	  good	  yields	  under	  suitable	  acidic	  or	  basic	  conditions.	  Thiodiazole	  16	  was	  obtained	  by	  irradiating	  (1–2.5	  minutes	  at	   300	   W	   of	   power)	   the	   thiosemicarbazides	   together	   with	   concentrated	   H2SO4,	   while	   the	  respective	   triazole	   17	   was	   obtained	   by	   irradiating	   the	  mixture	   for	   2.5	  min	   at	   300	  W	  with	  NaOH	   (2	   N)	   (Scheme	   13).	   The	   reaction	   was	   completed	   in	   1.5	   hours	   under	   conventional	  heating,	  while	  the	  reaction	  in	  a	  domestic	  MW	  oven	  was	  much	  faster	  and	  gave	  higher	  yields.	  Moreover,	  the	  fluorine	  substituent	  in	  the	  molecules	  provides	  the	  unique	  conditions	  of	  thermal	  stability	   and	   lipophilicity.35	  All	   the	   compounds	   exhibit	  moderate	   to	   excellent	   antimicrobial	  activity	  against	  a	  range	  of	  bacterial	  and	  fungal	  strains.	  
	  	  Analogously	   Jubie	   and	   co-­‐workers	  prepared	   a	   series	   of	  Mannich	  bases	   of	   Ciprofloxacin	   and	  Norfloxacin	  with	  various	  benzimidazoles	  under	  MW	  irradiation	  (domestic	  oven)	  with	  the	  aim	  of	   generating	   modified	   fluroquinolone	   rings.36	   The	   substituted	   benzimidazoles	   18	   were	  prepared	  via	  irradiation	  of	  the	  o-­‐phenylenediamine	  and	  an	  appropriate	  acid	  at	  350	  W	  for	  25	  minutes	  (Scheme	  14).	  The	  benzimidazole	  derivatives	  were	  suspended	   in	  an	  ethanolic	  solution	  of	  Ciprofloxacin	  (or	  Norfloxacin)	   and	   formaldehyde	   and	   irradiated	   for	   3?5	   min	   to	   generate	   the	   corresponding	  benzimidazole	  substituted	  fluoroquinolones	  (Fig.	  1).	  All	   the	  derivatives	  showed	  more	  highly	  marked	   activity	   with	   respect	   to	   the	   standards	   Norfloxacin	   and	   Ciprofloxacin,	   in	   particular	  when	  used	  against	  Candida	  albicans.	  All	  the	  compounds	  obtained	  showed	  some	  antibacterial	  activity.	  
	  
	  Many	  nucleoside	  analogues	  that	  have	  been	  functionalised	   at	   the	   5-­‐position	   of	  pyrimidine	   nucleobases	   maintain	   the	  Watson–	   Crick	   base	   pairing37	   and	   have	  shown	   potent	   activity	   against	   many	  viruses,38	   and	   bacterial	   infections	   too.39	  Krim	  et	  al.	  aimed	  to	  design	  a	  new	  class	  of	  fluorescent	  nucleosides	  with	  antibacterial	  activity	   and	   have	   performed	   the	  functionalisation	   of	   the	   benzimidazole	  ring	   (C-­‐2)	   to	   the	   uridine	   (C-­‐5).40	  Benzimidazole	   was	   chosen	   for	   its	   wide	   spectra	   of	   biological	   activity,	   and	   attention	   was	  focused	   on	   the	   condensation	   step	   between	   o-­‐phenylenediamine	   and	   3,5-­‐bis-­‐O-­‐(tert-­‐butyldimethylsilyl)-­‐5-­‐	  (formyl)-­‐2-­‐deoxyuridine	  (Scheme	  15).	  
	  The	  reaction	  was	  carried	  out	  neat,	  in	  the	  presence	  of	  NaHSO3,	  under	  MW	  irradiation	  (100	  °C	  for	  2	  min,	  mono-­‐mode	  CEM-­‐Discover);	  products	  19	  were	  obtained	  in	  good	  to	  excellent	  yields	  (67–90%).	  The	   functionalisation	  of	   the	  C-­‐5	  position	  with	  an	  aromatic	  structure	  ensured	   the	  desired	   fluorescence	   properties.	   Some	  products	   showed	   potential	   antibacterial	   activity,	   but	  no	  antiviral	  action	  was	  observed.	  Coumarin	   and	   quinazoline	   rings	   were	   combined	   in	   a	   single	   scaffold	   in	   a	   new	   group	   of	  molecules	  designed	  by	  Rajitha	  et	  al.41	  The	  appropriate	  previously	  prepared	  substituted	  2-­‐(2-­‐oxo-­‐2H-­‐	   chromen-­‐3-­‐yl)-­‐4H-­‐benzo[d][1,3]oxazin-­‐4-­‐ones	   were	   either	   functionalised	   with	   o-­‐phenylenediamine	   or	   with	   benzo[c][1,2,5]	   thiadiazole-­‐4,5-­‐diamine	   to	   form	   the	   desired	  products.	   The	   reactions	   were	   carried	   out	   under	   conventional	   conditions	   and	   dielectric	  heating;	  the	  results	  were	  compared	  and	  cellulose	  sulphuric	  acid	  was	  used	  as	  a	  green	  catalyst.	  The	   conditions	   are	   summarized	   in	   Scheme	  16.	  MW	  condensation	  was	  particularly	   efficient;	  yields	  were	  increased	  in	  all	  cases	  and	  reaction	  times	  were	  drastically	  reduced	  from	  5–6	  hours	  under	  conventional	  heating	  to	  just	  a	  few	  minutes.	  All	   the	   products	   were	   evaluated	   for	   their	   activity	   against	   a	   panel	   of	   bacterial	   and	   fungal	  strains	  and	  it	  was	  revealed	  that	  the	  highest	  activity	  occurred	  in	  products	  containing	  Br	  or	  Cl	  substituents	  in	  the	  R1	  and	  R2	  positions.	  
	  
	  
	  Benzofuran	   and	   pyrazoline	   derivatives	   are	   well	   known	   for	   their	   biological	   activity.42	   The	  insertion	  of	  a	  second	  heterocyclic	  ring	  in	  their	  structure	  was	  used	  to	  boost	  the	  effect	  against	  multidrug	  resistant	  bacteria.43	  Manna	  et	  al.	  described	  the	  synthesis	  of	  pyrazoline	  containing	  benzofuran	  using	  an	  indo-­‐	  phenazine	  ring	  (Scheme	  17).44	  
	  	  The	   reactions	   were	   carried	   out	   and	   the	   classical	   synthetic	   route	   and	   the	   MW-­‐assisted	  procedure	   (domestic	  MW	  oven)	  were	  compared.	  First	  of	   all,	   isatin	  and	  o-­‐phenylenediamine	  were	   irradiated	   with	  MW	   for	   6	  minutes	   (160	  W)	   providing	   indophenazine	   22	   in	   excellent	  yields	  (MW	  97%,	  oil	  bath	  70%).	  6-­‐	  Carbethoxymethyl	  indophenazine,	  previously	  synthesised	  from	  22	  and	  ethyl	  chloroacetate	  (yield:	  MW	  88%;	  oil	  bath	  64%),	  was	  treated	  in	  the	  presence	  of	   hydrazine	   hydrate	   in	   ethanol	   to	   generate	   pure	   indophenazine-­‐6-­‐acetic	   acid	   hydrazide	   in	  just	  a	  few	  seconds	  (yield:	  MW	  94%;	  oil	  bath	  66%).	  Benzofuranchalcones	  and	  indophenazine-­‐6-­‐acetic	   acid	   hydrazide	   were	   irradiated	   by	   MW	   (320	   W)	   and	   very	   rapidly	   generated	   the	  desired	   products	   23	   in	   good	   to	   excellent	   yields	   (20–30	   s	   vs.	   8–9.5	   h	   under	   conventional	  conditions).	  Five	  of	  the	  synthesised	  compounds	  (R	  1⁄4	  –OH	  (o),	  –NO2	  (m)	  and	  (o),	  –OCH3	  (	  p)	  and	  –H)	  showed	  good	  antibacterial	  activity	  (against	  Gram+	  and	  Gram-	  bacteria)	  and	  low	  MIC	  values	  that	  are	  comparable	  with	  Sparfloxacin	  and	  Norfloxacin.	  Gupta	   showed	   an	   interest	   in	   discovering	   the	   nature	   of	   any	   combined	   effect	   of	   having	   both	  triazepine	  and	  triazole	  moieties	  in	  a	  single	  framework	  on	  the	  physiological	  activity.	  The	  work	  reported	   a	  mild	   and	   rapid	   procedure	   for	   the	   synthesis	   of	   3,6-­‐	   diaryl-­‐5H-­‐[1,2,4]triazolo[4,3-­‐b[1,2,4]triazepines	   from	   b-­‐chlorocinnamaldehydes	   and	   5-­‐aryl-­‐3,4-­‐diamino-­‐1,2,4-­‐triazoles	   as	  outlined	  in	  Scheme	  18.45	  
	  	  The	   cyclisation	  was	   carried	   out	   under	   dielectric	   heating	   (domestic	  MW	   oven	   at	   640	  W)	   in	  DMF	  using	  p-­‐TsOH	  as	  the	  catalyst.	  For	  the	  sake	  of	  comparison	  with	  conventional	  heating,	  the	  reactions	   were	   also	   carried	   out	   in	   an	   oil	   bath	   using	   80°C	   as	   the	   optimum	   reaction	  temperature.	   Some	  of	   the	   compounds	  obtained	   showed	  excellent	   antifungal	   activity	   against	  
Aspergillus	  niger	  and	  Penicillium	  species,	  and	  good	   to	  moderate	  activity	  against	  Aspergillus	  flavus	  and	  Rhizopus	  species.	  By	  using	  a	  similar	  MW	  procedure	  (640	  W,	  domestic	  MW	  oven),	  the	  same	  author	  synthesised	  1-­‐substitued-­‐8-­‐aryl-­‐3-­‐alkyl/aryl-­‐4H-­‐pyrazolo[4,5-­‐f][1,2,4]triazolo[4,3-­‐b][1,2,4]triazepines	  (Scheme	  19),46	  using	  basic	  alumina	  as	  a	  solid	  support.	  The	  authors	  attribute	  the	  high	  yields	  and	   the	  rapidity	  of	   the	  reactions	   to	   the	  polar	  nature	  of	   the	  molecules	  and	   to	   their	  ability	   to	  interact	  with	  MW.	  The	   products	   obtained	   are	  made	   up	   of	   three	   heterocyclic	  moieties,	   each	  associated	  with	  a	  broad	  activity	  spectrum,	  while	  known	  for	  the	  antifungal	  activity	  when	  found	  together.	  The	   synthesised	   compounds	  were	  evaluated	   for	   their	   antifungal	   activity	   against	  Aspergillus	  flavus,	  Aspergillus	  niger,	  Rhizopus	  species	  and	  Penicillium	  species	  and	  showed	  good	  activity.	  Behbehani	   et	   al.	   performed	  2-­‐arylhydrazononitrile	  decoration	  using	  different	   techniques.47	  The	  hydrazone	  derivative,	  prepared	  from	  the	  cyanoacetylindole,	  is	  an	  important	  synthon	  for	  the	  preparation	  of	  indolylheteroaromatic	  structures.	  In	  fact,	  when	  mixed	  with	  hydroxylamine	  hydrochloride	  and	  sodium	  acetate	  and	  irradiated	  for	  60	  seconds	  at	  120°C	  (mono-­‐mode	  cavity	  Explorer	  CEM	  MW	  Synthesizer)	  it	  afforded	  the	  1,2,3-­‐triazole	  26	  (Scheme	  20).	  
	  	  The	  triazole	  was	  converted	  to	  the	  cyanoacetamide	  derivative	  and	  then	  to	  the	  corresponding	  enamines	  (E-­‐isomer)	  in	  excellent	  yields	  	  after	  a	  few	  seconds	  of	  MW	  irradiation.	  Under	  conven-­‐	  tional	   conditions	   the	   enamines,	  mixed	  with	   hydrazine	   hydrate	   in	   refluxing	   ethanol,	   yielded	  the	   acyclic	   hydrazine	   derivatives	   that	   underwent	   cyclization	   to	   form	   the	   corresponding	  amino-­‐	  pyrazole	  27,	  when	  stirred	  in	  refluxing	  pyridine	  (Scheme	  21).	  	  The	   same	   reaction,	   carried	   out	   under	  MW	  irradiation	  (120?C,	  90	  s),	  afforded	  the	   corresponding	   triazolo-­‐pyridone	  derivatives	  28.	  The	  reactivity	  seemed	  to	  be	  strongly	  influenced	  by	  the	  technique	  used	   for	   the	   reaction.	   The	   authors	  believe	   that	   upon	   the	   use	   of	   MW	  irradiation,	   the	   acyclic	   hydrazine	  derivatives	   tautomerize	   to	   produce	   a	  hydrazone	  intermediate	  that	  cyclises	  to	  generate	   28.	   To	   achieve	   the	   same	  product	   it	   was	   necessary	   to	   stir	   the	  acyclic	  hydrazine	  in	  refluxing	  DMF	  with	  anhydrous	   sodium	   acetate	   (oil	   bath	   3	  h).	  Pyrimidine	   rings	  were	   inserted	   into	  27	   	  
by	   reacting	   these	   substances	   with	   3-­‐(dimethylamino)-­‐acrolein.	   This	   process	   yiel-­‐	   ded	   the	  corresponding	   pyrimidinopyrazole	   29	   (oil	   bath	   48	   h,	   MW	   2	   min	   at	   120°C).	   In	   a	   similar	  manner,	   the	   reactions	  of	  27	  with	  enaminones,	   carried	  out	   either	   thermally	   (48	  h)	  or	  under	  MW	  irradiation	   (2	  min	  at	  120°C),	  yielded	   the	  corresponding	  pyrazolo[1,5-­‐a]pyrimidines	  30.	  This	  strategy	  will	  be	  considered	  in	  the	  future	  for	  the	  preparation	  of	  pyridone-­‐triazole;	  further	  optimisation	  is	  required,	  however.	  All	   products	  were	   tested	   for	   antimicrobial	   activity	   and,	   in	   some	   cases,	   a	   significant	   activity	  against	  Gram-,	  Gram+	  bacteria	  and	  yeast	  was	  found.	  A	   three-­‐component	  MW-­‐assisted	  reaction	  was	  used	  by	  Basavaraja	  et	  al.	   for	   the	  synthesis	  of	  pyrimidine	   derivatives.48	   The	   first	   step	   generated	   the	   pyrimidine	   core	   from	   ethyl	  cyanoacetate,	  thiourea	  and	  a	  suitable	  aldehyde	  under	  basic	  conditions	  (Scheme	  22).	  	  
	  	  While	   12	   hours	   were	   required	   for	   complete	   cyclisation	   under	   reflux	   conditions;	   MW	  dramatically	  reduced	  the	  reaction	  time	  and	  the	  desired	  products	  31	  were	  achieved	   in	  a	   few	  minutes	  (3	  intermittent	  cycles	  of	  2	  min	  at	  160	  W).	  After	   preliminary	   methylation,	   intermediates	   31	   subsequently	   underwent	   an	   elimination	  reaction	   with	   heterocyclic	   secondary	   amines	   (piperazine,	   morpholine	   and	   N-­‐methyl-­‐	  piperazine)	   to	   generate	   various	   pyrimidine	   analogues.	   The	   biological	   profile	   of	   the	  synthesised	  pyrimidine	  showed	  moderate	  activity	  against	  Staphylococcus	  aureus	  and	  Bacillus	  subtilis,	  and	  significant	  antifungal	  activity	  against	  Candida	  albicans	  and	  Aspergillus	  niger.	  De	  Keersmaecker	  et	  al.	  have	  recently	  proposed	  a	  procedure	  for	  the	  synthesis	  of	  substituted	  2-­‐amino-­‐1H-­‐imidazoles	   under	   MW	   irradiation.49	   The	   protocol	   is	   based	   on	   the	  cyclocondensation	  of	  2-­‐aminopyrimidines	  and	  α-­‐bromocarbonyl	  compounds,	  followed	  by	  the	  cleavage	  of	  the	  intermediary	  imidazo[1,2-­‐a]pyrimidinium	  salts	  using	  an	  excess	  of	  hydrazine.	  This	   step	   was	   accurately	   studied,	   and	   MW	   and	   conventional	   procedures	   were	   compared	  under	   different	   conditions.	   Just	   a	   few	   minutes	   of	   MW	   irradiation	   at	   80?C	   (multimode	  Milestone	  MicroSYNTH,	  equipped	  with	  a	  IR	  pyrometer	  and	  fiberoptic	  thermometer	  inside	  the	  reaction	  vial)	  were	  necessary	   to	  afford	  2-­‐amino-­‐1H-­‐imidazoles	  with	   increased	  yields	  of	  10?15%	  (Scheme	  23).50	  The	  authors	  additionally	  proposed	  the	  synthesis	  of	  N1-­‐	  substituted	  2-­‐aminoimidazoles	  from	  2-­‐amino-­‐pyrimidines	  via	  N1-­‐substituted	  imidazo[1,2-­‐a]pyrimidinium	  salts.49,51	  Harsh	  condi-­‐	  tions	  and	  several	  steps	  were	  necessary	  to	  obtain	  the,	  mainly,	  hydroxy	  salts	  of	  the	  imidazo[1,2-­‐a]pyrimidine	   when	   the	   reactions	   were	   carried	   out	   in	   an	   oil	   bath,	   whereas	  MW	   irradiation	  (150°C,	   30	   min)	   selectively	   afforded	   the	   imidazo[1,2-­‐a]pyrimidinium	   salts,	   in	   a	   one-­‐pot	  reaction,	  which	   underwent	   cleavage	  with	   hydrazine	   to	   form	   the	   desired	   products	   (Scheme	  24).	  
	  	  The	   2-­‐aminoimidazole	   derivative	   showed	   moderate	   biofilm	   inhibitory	   activity	   against	  Salmonella	  typhimurium	  and	  Pseudomonas	  aeruginosa,	  while	  the	  4,5-­‐disubstituted	  2-­‐amino-­‐1H-­‐	   imidazoles	   were	   in	   general	   more	   active	   against	   Salmonella	   typhimurium	   biofilm	  formation,	   but	   were	   also	   toxic	   to	   Salmo-­‐	   nella.	   The	   inhibition	   of	   biofilm	   formation	   in	  Salmonella	   typhimurium	   and	   Pseudomonas	   aeruginosa	  was	   enhanced	   by	   inserting	   alkyl	   or	  cycloalkyl	  pendants	  (medium	  length)	  at	  the	  N1-­‐position.	  Condensed	   thienopyrimidines	   have	   shown	   some	   interesting	   biological	   activity	   as	  antimicrobial	  and	  non-­‐steroidal	  antiinflammatory	  agents,52	  and	  the	  drug	  design	  possibilities	  in	   this	   field	   led	   Prasad	   and	   Kishore	   to	   outline	   an	   efficient	   MW	   route	   for	   pyrimido[1,2-­‐c]thieno[3,2-­‐e]pyrimidine	  synthesis	  (Scheme	  25).53	  All	  reactions	  were	  performed	  in	  a	  CEM-­‐Discover	  (reaction	  time	  ranged	  from	  10	  s	  to	  10	  min)	  under	  continuous	  internal	  temperature	  control.	  
	  	  2-­‐Amino-­‐3-­‐carbethoxy-­‐4,5,6,7-­‐tetrahydrobenzo[b]thiophene	   was	   irradiated	   at	   120°C	   (MW	  50–120	  s)	  with	  various	  aryl/alkyl	  nitriles	  with	  a	  catalytic	  amount	  of	  potassium	  t-­‐butoxide	  to	  form	   the	   derivative	   34.	   The	   hydroxyl	   group	  was	   converted	   to	   aminoalcohol	   via	   the	   chloro-­‐derivative	   (MW	  120°C	  10–30	  s).	  The	   last	   cyclisation	  of	   the	  aminopropanolic	   chain	  was	  also	  performed	   under	  MW	   irradiation	   in	   the	   presence	   of	   silica	   gel	   (60/120	  mesh)	   and	   POCl3	   at	  120°C	  (10–30	  s).	   It	   is	  evident	  that	  all	   the	  crucial	  synthetic	  steps	  were	  strongly	  promoted	  by	  the	  use	  of	  MW.	  P	  ́erez	   et	   al.	   described	   the	   preparation	   of	   9-­‐aryl-­‐6-­‐chloropurines	   following	   alternative	  synthetic	   approaches.54	   One	   of	   these	   procedures	   consisted	   of	   a	   two-­‐step	   MW-­‐assisted	  reaction	   (mono-­‐mode	   Biotage	   Initiator	   2.0).	   The	   aniline	   derivatives	   were	   first	   bound	   to	  dichloroaminopyrimidines	  and	  then	  cyclisation	  to	  9-­‐arylpurines	  was	  carried	  out	  under	  MW	  in	  the	  presence	  of	  trimethylorthoformate	  in	  acetic	  anhydride	  (120°C,	  1	  h)	  (Scheme	  26).	  
Alternatively,	   the	   corresponding	   8-­‐oxopurine	   was	   obtained	   by	   irradiating	   the	  aminopyrimidine	  in	  the	  presence	  of	  triphosgene	  in	  THF	  (120°C,	  20	  min)	  (Scheme	  27).	  
	  	  The	   same	   authors	   have	   described	   a	   series	   of	   compounds	   containing	   an	   acetanilide	   as	   their	  aryl	   substituent.	   The	   reactions	   were	   carried	   out	   with	   30-­‐amino-­‐acetanilide	   and	   either	  dichloropyrimidine	  or	  its	  2-­‐methyl	  analogue	  in	  an	  acetic	  acid/isobutanol	  solvent	  mixture.	  The	  corresponding	   acetamide	  was	   obtained	   in	   good	   yields	   under	  MW	   irradiation	   (150°C	   for	   15	  min).	   The	   acetamide	   cyclisation	   was	   performed	   under	   dielectric	   heating	   with	  trimethylorthoformate	  and	  ethanosulphuric	  acid	  (120°C,	  1	  h)	  (Scheme	  28).	  The	  N-­‐alkylation	  of	  the	  purine	  38	  gave	  a	  compound	  which	  showed	  selective	  antiviral	  activity.	  
	  	  A	  third	  series	  of	  analogues	  contain	  an	  oxazolidin-­‐2-­‐one	  on	  the	  aryl	  ring,	  part	  of	  more	  complex	  N-­‐alkyl	  amide	  structure	  that	  underwent	  cyclization	  to	  a	  tetra-­‐azabyciclic	  derivative.	  Oxazoli-­‐	  dinone	   39	   was	   rapidly	   obtained	   (120°C,	   2	   h)	   in	   good	   yields	   under	   MW	   irradiation.	   The	  reaction	   was	   carried	   out	   by	   irradiating	   the	   30-­‐amino-­‐acetanilide	   in	   the	   presence	   of	   2-­‐chloroethyl	   chloroformate,	   Cs2CO3	   and	  DIPEA.	  The	   same	   reaction	   required	  12	  min	   in	   an	  oil	  bath.	  The	  diaminopyrimidine	  derivative	  was	  obtained	  in	  moderate	  yields	  when	  compound	  39	  was	  irradiated	   together	  with	   dichloropyrimidines.	   These	   intermediates	   gave	   a	   purine	   40	   in	   the	  presence	   of	   trimethylorthoformate	   and	   ethanosulfonic	   acid	   under	   MW	   (120°C,	   30	   min).	  Alternatively,	   the	  use	  of	   triphosgene	   led	   to	   the	  8-­‐oxopurine	  41	   (120°C,	   from	  20	   to	  45	  min)	  (Scheme	  29).	  
	  	  Most	  of	   these	  compounds	  showed	  selective	  antiviral	  activity.	  The	  mechanism	  of	  action	  of	  9-­‐arylpurines	  was	  also	  investigated	  and	  preliminary	  results	  showed	  that	  these	  compounds	  stop	  infectious	  virus	  particles	  to	  assemble	  correctly.	  D'Accorso	  et	  al.	  used	  an	  earlier	  report,55	  as	  a	  base	  to	  develop	  a	  convergent	  procedure	  for	  the	  synthesis	  of	  imidazo[2,1-­‐b]thiazoles.56	  The	  cyclisation	  step	  between	  the	  carbohydrate	  and	  N-­‐(5-­‐	   arylthiazol-­‐2-­‐yl)-­‐N,N-­‐dimethyl	   formamidine	  was	   carried	   out	   under	   both	   conductive	   and	  dielectric	  heating	  (CEM-­‐Discover).	  With	   the	  non-­‐conventional	  procedure,	   the	  reactions	  were	  carried	  out	  at	  105?C	   for	  90?150	  min	  (Scheme	  30),	  and	  although	  the	  yields	  were	  not	  significantly	   improved,	  the	  reaction	  was	  much	   faster.	  The	   coupled	  positions	  of	   the	   carbohydrate	   and	   the	  heterocyclic	  moieties	  were	  inverted	  (Scheme	  31)	  with	  an	  eye	  for	  evaluating	  how	  the	  substituents	  in	  the	  heterocyclic	  ring	  could	  positively	   affect	   the	   antiviral	   activity.	  The	   reactions,	   in	   this	   case,	  were	   carried	  out	  by	  irradiating	  the	  mixture	  at	  100°C	  for	  90	  minutes.	  
	  
	  All	  the	  derivatives	  exhibited	  a	  wide	  range	  of	  effective	  antiviral	  concentrations.	  Furthermore,	  brominated	   and	   chlorinated	   compounds	   showed	   enhanced	   antiviral	   activity	   and	   selectivity	  with	  respect	   to	   ribavirin,	   the	  only	  drug	   in	  clinical	  use	   for	  arena	  virus	   treatment,	  which	  was	  also	  evaluated	  as	  a	  reference	  substance.	  	  
3	  Antinflammatory	  activity	  The	   search	   for	   non-­‐steroidal	   agents	   that	   possess	   both	   anti-­‐fungal	   and	   anti-­‐inflammatory	  activity	  has	   long	  been	  pursued.	  Of	  the	  arsenal	  of	  heterocyclic	  derivatives	  available,	   this	  dual	  effect	   is	   found	   in	   the	   drug	   imidazole.	   Several	   attempts	   to	   synthesise	   imidazoles	   and	   fused	  imizazole	  derivatives	  under	  MW	  irradiation	  have	  been	  described	  in	  the	  literature.	  A	  multicomponent	   single	   step	   reaction	  was	  performed	  by	  Tripathy	   et	   al.	   to	   synthesise	  new	  analgesic	  and	  anti-­‐inflammatory	  compounds	  made	  up	  of	  variously	  substituted	  imidazoles.57	  All	  reactants	  were	  placed	  in	  a	  long	  necked	  glass	  vial	  and	  irradiated	  for	  8	  minutes	  at	  120?C	  and	  19	  bar	  (Biotage,	  Emrys	  Optimizer)	  (Scheme	  32).	  	  
	  In	   the	   first	   step,	   ammonium	   acetate	   released	   ammonia	   under	   hot,	   acidic	   conditions.	  Subsequently,	   the	  NH3	  reacted	  with	  an	  aldehyde	  to	  form	  an	  imine,	  while	  the	  other	  molecule	  interacts	   with	   the	   benzyl	   carbonyl	   group	   to	   form	   a	   second	   imine.	   The	   imidazole	   ring	   was	  synthesised	  via	  the	  cyclisation	  of	  the	  two	  imines,	  generated	  in	  situ,	  giving	  yields	  of	  60–70%.	  The	   amines	   used	   for	   the	   reaction	  were	   aniline,	   p-­‐isopropyl	   aniline,	   benzyl	   amine,	   p-­‐chloro	  aniline,	  1(H)-­‐furfuryl	  amine	  and	  tryptamine,	  respectively.	  All	   the	   products	  were	   screened	   for	   anti-­‐inflammatory	   properties	   using	   the	   rat	   paw	   edema	  method	  and	  showed	  remarkable	  activity.	  The	  same	  authors	  performed	   the	  one	  pot	  synthesis	  of	   tetra-­‐substituted	   imidazoles	   (Scheme	  33).58	  	  
	  	  The	  reaction	  proceeded	  via	  a	  four-­‐component	  condensation	  reaction	  to	  form	  the	  imid-­‐	  azole	  ring.	  MW	  enables	  easy	  access	  to	  several	  substituted	  imidazoles	   in	  short	  reaction	  times,	  high	  product	  purities	  and	  yields,	  whereas	  the	  same	  reactions	  proceeded	  very	  slowly	  under	  reflux	  
heating.	   Several	   amines	  were	   used	   for	   substitution	   at	   the	   imidazole	   ring	   position	   1.	   It	  was	  observed	   that	   simple	   substituted	   anilines	   and	   alkylamines	   gave	  higher	   yields	   than	   complex	  heterocyclic	  amines.	  The	  4-­‐substituted	  anilines	  gave	  higher	  yields	  and	  easier	  purification.	  Five	  compounds	  were	  synthesised	  using	  various	  amines	  and	  p-­‐hydroxybenzaldehyde	  (yields	  80?85%).	  Two	  compounds	  were	  synthesised	  using	  amines	  and	  p-­‐fluorobenzaldehyde	  (yields	  75?80%),	  and	  seventeen	  compounds	  were	  synthesized	  using	  various	  amines	  and	  vanillin	  (yield	  70?75%).	  MW	   again	   strongly	   promoted	   the	   reactions	   and	   reduced	   the	   amount	   of	   solvent	   used.	   All	  compounds	  showed	  anti-­‐inflammatory	  activity	  and	  significantly	  reduced	  the	  rat	  paw	  volume	  when	  administered	  orally.	  A	   solvent	   free	   MW	   assisted	   method	   promoting	   cyclization	   of	   polycyclic	   benzimidazole	  derivatives	   was	   published	   by	   Sondhi	   et	   al.	   with	   the	   goal	   of	   identifying	   molecules	   with	  anticancer	   and	   anti-­‐inflammatory	   activity.59	   The	   cyclisation	   reactions	  were	   carried	   out	   by	  irradiating	  a	  mixture	  (1	  :	  1	  molar	  ratio),	  previously	  mixed	  in	  a	  mortar,	  in	  a	  MW	  oven	  (4–8	  min,	  850	   W)	   (Scheme	   34).	   Various	   diamines	   were	   mixed	   with	   succinic	   acid	   to	   obtain	   tricyclic	  benzimidazole	   derivatives	   and	   with	   either	   4-­‐carboxyphenyl	   acetic	   acid	   or	   2,3-­‐pyrazinedicarboxylic	   acid	   to	   obtain	   tetracyclic	   derivatives.	   A	   number	   of	   tricyclic	   and	   tetra-­‐	  cyclic	  benzimidazole	  derivatives	  were	  synthesised	  rapidly	  and	  in	  good	  yields	  (80–98%).	  
	  	  All	  products	  were	  tested	  for	  anti-­‐inflammatory	  and	  anticancer	  activity.	  Compounds	  47	  and	  48	  showed	  results	  that	  are	  comparable	  with	  the	  drug	  ibuprofen,	  whereas	  compound	  49	  showed	  interesting	   anticancer	   activity	   against	   human	   ovary	   and	   breast	   cancer	   cell	   lines.	   Burke	   has	  recently	  reported	  the	  identification	  of	  an	  imidazoquinoxaline	  based	  inhibitor	  of	  IkB	  kinase	  2	  (IKK2)	   as	   an	   orally	   active	   therapeutic	   agent	   for	   the	   treatment	   of	   inflammatory	   diseases.60	  Despite	  promising	  in	  vitro	  efficacy	  studies	  in	  both	  acute	  and	  chronic	  preclinical	  inflammation	  models,	   the	   compound	   has	   relatively	  weak	   potency	   in	   vivo.	   Thiophene	   and	   pyrazolopurine	  chemotypes	   revealed	   themselves	   to	   be	   potent	   and	   selective	   inhibitors	   of	   IKK2,	   but	   their	  preparation	  was	   tedious,	   and	  pharmacokinetic	   profiles	   and	   chemotype	   diversification	  were	  quite	  poor.	  Kempson	  et	  al.	  aimed	  to	  improve	  the	  low	  metabolic	  stability	  of	  the	  pyrazolopurine	  and	   thiophene	   tricycles	   and	   developed	   a	   new	   synthetic	   route	   to	   block	   their	   metabolism	  sites.61	   To	   test	   this	   hypothesis,	   a	   series	   of	   oxazole	   and	   imidazole	   tricycles	   were	   prepared	  under	   MW	   irradiation	   in	   the	   cyclisation	   step	   (Personal	   Chemistry	   Smith	   Synthesizer	  workstation)	  (Scheme	  35).	  
	  The	   oxazole	   was	  obtained	  from	  a	  penta-­‐substituted	   pyridine.	  The	   reaction	   was	  carried	   out	   under	  MW	  irradiation	   (220°C)	   in	  the	   presence	   of	  sodium	   carbonate	   in	  DMF.	   The	   imidazole	  was	   obtained	   by	  converting	   the	   amide	  substituent	   into	   the	  corresponding	  chloroimidate	  with	  thionyl	  chloride,	  followed	  by	  subsequent	  displacement	  with	  methylamine.	  Ring	   closure	   was	   carried	   out	   under	   MW	   (200°C,	   1	   h)	   in	   the	   presence	   of	   potassium	   tert-­‐butoxide	  affording	  51	  in	  good	  yields.	  These	   intermediates	  were	  properly	  modulated	  and	  showed	  improved	  potency	  against	   IKK2,	  however,	  pharmacokinetic	  profiles	  were	  not	  improved.	  Another	   example	   of	   MW	   promoted	   solvent	   free	   syntheses	   of	   new	   biologically	   active	  heterocycles	  has	  been	  published	  by	  Mathew	  et	  al.62	  Their	  attention	  was	  focused	  on	  the	  1,2,4-­‐triazole	   and	   1,3,4-­‐thiadiazole	   structures	  which	   display	   analogies	  with	   numerous	   important	  biological	  compounds	  (i.e.	  thiosemicarbazide	  and	  biguanide).	  The	   synthesis	   enabled	   two	   important,	   biologically	   active	   nuclei	   to	   be	   incorporated	   into	   a	  triazolothiadiazole	  structure.	  First	   of	   all,	   4-­‐amino-­‐3-­‐aryl/alkyl/heteroaryl	   substituted-­‐5-­‐mercapto-­‐1,2,4-­‐triazoles	   were	  prepared	  according	  to	  the	  Reid	  and	  Heindel	  procedure.63	  A	  solution	  of	  the	  products	  obtained	  and	   their	  respective	  aromatic	  acids	   in	  POCl3	  were	  mixed,	  adsorbed,	  dried	  with	  alumina	  and	  irradiated	   for	   30	   seconds	   with	   MW	   (total	   irradiation	   7–8	   min)	   providing	   products	   52–54	  (Scheme	  36).	  The	   same	   procedure	   was	   used	   for	   the	   syntheses	   of	   the	   corresponding	   5,6-­‐dihydro	  triazolothiadiazoles	  55	  and	  56.	  The	  corresponding	  products	  were	  obtained	  via	  the	  irradiation	  of	  the	  triazole	  with	  heteroaromatic	  aldehydes	  in	  the	  presence	  of	  p-­‐TsOH	  in	  DMF	  for	  6	  minutes	  (Scheme	  37).	  
	  
	  
	  	  The	   conventional	   synthetic	   reflux	   procedures	   required	   prolonged	   reaction	   times	   (6?12	  hours),	  while	  the	  reactions	  were	  faster	  and	  cleaner	  under	  MW	  irradiation,	  making	  the	  latter	  an	  all-­‐round	  superior	  method.	  The	  products	  obtained	  were	  subsequently	  screened	   for	   their	  biological	  activity.	  Compounds	  55	   gave	   the	   best	   results	   against	   both	   Gram+	   and	   Gram-	   bacteria	   in	   antimicrobial	   tests.	  Compounds	  56	  showed	  good	  anti-­‐inflammatory	  and	  analgesic	  activity.	  Maximum	  protection	  was	  observed	   in	   compounds	  with	  an	   indole	   ring	  at	   the	  6	  position	  of	   the	   triazolothiadiazole	  system	   56,	   while	   introducing	   electron	   donating	   groups	   to	   the	   indole	   caused	   anti-­‐inflammatory	  and	  analgesic	  activity	  to	  decrease.	  	  
4	  Drugs	  for	  cardiovascular	  diseases	  Cardiovascular	  diseases	  have	  long	  been	  the	  main	  cause	  of	  death	  in	  many	  developing	  countries	  and	  of	  disability	  in	  industrialised	  areas.	  Furthermore,	  major	  heart	  diseases	  carry	  a	  mortality	  risk	  that	  is	  comparable	  to	  the	  worst	  malignancies.	  Many	  N-­‐heterocyclic	  scaffolds	  that	  can	  be	  used	  in	  cardiovascular	  drug	  design	  have	  been	  obtained	  by	  MW-­‐assisted	  synthesis.	  Sujatha	  et	  al.64	  presented	  MW-­‐assisted	  synthesis	  of	  3,4-­‐	  dihydropyrimidinones	  (DHPMs)	  that	  can	   be	   seen	   in	   Scheme	   38.	   DHPMs	   were	   easily	   prepared	   by	   heating	   1,3-­‐dicarbonyl	  compounds,	  urea	  and	  aromatic	  aldehydes	  in	  acetic	  acid	  under	  MW	  irradiation.	  Reactions	  were	  carried	  out	  in	  a	  modified	  domestic	  MW	  oven	  and	  monitored	  by	  TLC	  up	  to	  completion	  (time	  5–7	   min	   with	   a	   pulse	   rate	   of	   40	   s	   and	   power	   30%).	   DHPMs,	   also	   called	   Biginelli	   products,	  possess	   interesting	  biological	  applications.	  The	  apparent	  structural	  similarities	  of	  DHPMs	  to	  the	  well-­‐known	  Hantzsch-­‐type	   dihydropyridines,	  which	   act	   as	   calcium	   channel	  modulators,	  can	  be	  considered	  as	  a	  very	  attractive	   feature	   in	  medicinal	  chemistry.	  Dihydropyridines	  are	  perhaps	  the	  most	  potent	  of	  Ca2+	  channel	  blockers,	  although	  research	  into	  new	  drugs	  that	  may	  increase	   cardiac	   muscle	   contractility	   and	   show	   a	   broad	   therapeutic	   index	   is	   still	   ongoing.	  These	  authors	  presented	  the	  cardiotonic	  activity	  of	  DHPMs	  on	  an	  isolated	  perfused	  frog	  heart.	  The	  effects	  of	  DHPMs	  were	  evaluated	  on	  this	  model	  at	  various	  dose	  levels	  and	  compared	  with	  the	  activity	  of	  digoxin	  under	   identical	   experimental	   conditions.	  The	   results	  obtained	  clearly	  indicated	  that	  compounds	  57a–f	  showed	  good	  cardiotonic	  activity,	  whereas	  compounds	  57h	  and	   57i	   showed	   themselves	   to	   be	   β-­‐adrenergic	   receptor	   antagonists.	   Compound	   57d	  appeared	  to	  be	  more	  effective	  than	  digoxin	  and	  the	  most	  interesting	  derivative	  in	  the	  series.	  In	   5	   minutes	   of	   MW	   irradiation	   (Emrys	   optimiser	   –	   Biotage	   AB)	   at	   180°C	   Epple	   et	   al.65	  obtained	   the	   thiazole	   ring	   via	   the	   Hantzsch	   condensation	   under	   MW	   from	   a	   thioamide	  intermediate	  and	  a	  wide	  range	  of	  R-­‐bromoketones	  (Scheme	  39).	  	  	  
	  	  It	  was	  demonstrated	  that	  the	  thiazole	  derivative	  was	  accommodated	  in	  a	   large	  hydrophobic	  pocket	   present	   in	   peroxisome	   proliferator-­‐activated	   receptors	   (PPARs).	   These	   are	   key	  regulators	  of	  the	  genes	  involved	  in	  energy	  homeostasis	  and,	  as	  such,	  provide	  excellent	  targets	  for	  the	  potential	  treatment	  of	  metabolic	  syndrome,	  which	  significantly	  increases	  the	  chances	  of	  developing	  cardiovascular	  diseases.	  More	  than	  150	  analogues	  were	  synthesised	  according	  to	   the	  MW-­‐assisted	   cyclisation	   protocol	   reported	   in	   Scheme	   39,	   and	  were	   used,	   in	   turn,	   to	  synthesise	   a	   novel	   series	   of	   selective	   PPARd	   agonists.	   Several	   compounds	   are	   currently	  undergoing	  additional	  evaluation	  to	   further	  elucidate	  the	  role	  of	  PPARd	  in	  glucose	  and	   lipid	  metabolism	   and	   assess	   the	   potential	   of	   developing	   this	   series	   for	   treatment	   of	   diseases	  associated	  with	  metabolic	  syndrome.	  Cyclic	   nucleotide	   phosphodiesterases	   (PDEs)	   are	   enzymes	   that	   catalyse	   the	   hydrolysis	   of	  cyclic	  nucleotides,	  cAMP	  and	  cGMP,	  to	  their	  respective	  50-­‐nucleoside	  monophosphates	  via	  the	  cleavage	  of	  the	  phosphodiester	  bond	  at	  the	  30-­‐position.	  The	  main	  therapeutic	  indications	  for	  PDE5	   inhibitors	   are	   the	   treatment	   of	   erectile	   dysfunction	   and	   idiopathic	   pulmonary	  hypertension,	  although	  several	  other	  potential	  applications	  have	  been	  identified	  as	  well,	  such	  as	  for	  the	  treatment	  of	  systemic	  hypertension	  and	  prostate	  hyperplasia.	  Sidelnafil	   is	   a	  well	   known	  phosphodiesterase	  5	   (PDE5)	   inhibitor,	   therefore,	  with	   the	  aim	  of	  obtaining	  analogues,	  Flores	  Toque	  et	  al.66	  optimised	  MW-­‐assisted	  cyclisation	  of	  4-­‐(2-­‐ethoxy-­‐	  benzamido)-­‐1-­‐methyl-­‐3-­‐propyl-­‐1H-­‐pyrazole-­‐5-­‐carboxamide	   to	   obtain	   the	   corresponding	  1H-­‐pyrazolo[4,3-­‐d]pyrimidin-­‐7(6H)-­‐	   one	   59	   (Scheme	   40).	   The	   synthesis	   was	   performed	   at	  100?C	  in	  a	  multimode	  MW	  oven	  (300	  W,	  ETHOS	  1600,	  Milestone).	  The	  MW-­‐assisted	  reaction	  was	  6	   times	   faster	   than	   the	   classical	   heating	  method,	   thus	   confirming	   the	   efficiency	  of	  MW	  flash-­‐heating	  chemistry.	  	  	  
	  Many	  sildenafil	  analogues	  obtained	  from	  this	  intermediate	  were	  tested	  in	   vitro	   to	   evaluate	   the	   inhibition	  of	   PDE5	   activity	   in	   human	  platelets,	   induced	   relaxation	   in	  rabbit	   corpora	   cavernosa	   and	  smooth	   muscle	   relaxation	   in	  isolated	  rabbit	  aortic	  rings.	  Several	  compounds	  exhibited	  good	  PDE5	   inhibitory	   activity	   that	   was	  just	  as	  potent	  as	  sildenafil	  and	  may	  offer	   new	   leads	   for	   the	  development	   of	   novel	   drug	  analogues.	   Since	   these	   compounds	   are	   more	   lipophilic	   than	   sildenafil,	   they	   may	   show	  improved	   oral	   bioavailability	   and	   prolonged	   action	   in	   vivo.	   Further	   studies	   on	   the	  pharmacokinetic	   profile	   of	   these	   compounds	   are	   required	   to	   fully	   investigate	   their	  therapeutic	  potential.	  	  
5	  Drugs	  for	  central	  nervous	  diseases	  Among	  the	  most	  frequently	  used	  therapeutic	  classes,	  CNS-­‐	  acting	  drugs	  correspond	  to	  ca.	  15%	  of	   the	   total.	   The	   remarkable	   ability	   of	   heterocyclic	   nuclei	   to	   serve	   as	  both	  biomimetics	   and	  active	   pharmacophores	   has	   largely	   contributed	   to	   their	   unique	   role	   as	   traditional	   key	  elements	   of	   numerous	   drugs.	   MW	   irradiation	   is	   clearly	   becoming	   a	   fundamental	   tool	   for	  optimising	  key	  steps	  in	  the	  syntheses	  involved	  in	  central	  nervous	  system	  drug	  design.	  Saari	  et	  al.67	  described	  an	  efficient	  MW-­‐assisted	  cyclisation	  of	  quinazoline	  at	  100°C	  (5	  min	  in	  a	  Biotage	  Initiator	  2.0).	  Specifically,	   4-­‐chloroquinazoline	   60	   was	   prepared	   from	   the	   corresponding	   2-­‐aminobenzonitrile,	   which	   was	   first	   converted	   to	   quinazolin-­‐4(3H)-­‐one	   by	   acid-­‐catalysed	  cyclisation	  with	  for-­‐	  mic	  acid	  under	  MW	  irradiation.	  Treatment	  of	  the	  intermediate	  under	  MW	  with	  an	  excess	  of	  POCl3	  in	  N,N-­‐diethylamine	  yielded	  the	  4-­‐chloroquinazoline	  60	  (Scheme	  41).	  Another	   MW-­‐assisted	   cyclisation	   performed	   by	   the	   authors	   was	   the	   synthesis	   of	   an	  isoquinoline	  heteroaromatic	  system.	  The	  cyclisation	  of	  (Z)-­‐methyl	  2-­‐[(5-­‐oxo-­‐2-­‐phenyloxazol-­‐4(5H)-­‐ylidene)-­‐methyl]-­‐benzoate	   with	   KOH	   in	   MeOH	   at	   100°C	   (Biotage	   Initiator	   2.0)	   was	  complete	   in	   only	   25	  min,	   giving	  methyl	   1-­‐oxo-­‐1,2-­‐dihydroisoquinoline-­‐3-­‐carboxylate	  which	  was	   chlorinated,	   via	   treatment	   with	   POCl3,	   and	   aromatised	   to	   give	   methyl	   1-­‐chloroisoquinoline-­‐3-­‐carboxylate	  61	  (Scheme	  42).	  	  
	  
	  	  The	   resulting	   quinolinic	   and	   isoquinolinic	   scaffolds	   were	   used	   to	   synthesise	   a	   series	   of	  quinolinyl,	   isoquinolinyl,	   quinoxalinyl	   and	   quinazoline	   phenyl	   amines	   as	   well	   as	   phenyl-­‐	  sulfanylquinolines	   and	   phenoxyquinolines.	   MW	   irradiation	   was	   used	   both	   for	   their	  cyclisation,	  as	  mentioned	  above,	  and	  functionalisation.	  This	  compound	  library	  was	  screened	  for	  cannabinoid	  2	  receptor	  (CB2)-­‐dependent	  G-­‐protein	  activity,	  which	  was	  determined	  using	  the	   GTPcS	   binding	   assay.	   CB2	   receptors	   have	   been	   recently	   identified	   in	   the	   brain	   and	   are	  thought	  to	  play	  a	  functional	  role	  in	  mental	  disorder	  and	  drug	  addiction.	  Recent	  investigations	  have	  demonstrated	  the	  therapeutic	  potential	  of	  selective	  CB2	  receptor	  ligands.	  CB2	  selective	  cannabinoids	  are	  expected	  to	  be	  devoid	  of	  undesired	  CB1-­‐mediated	  psychotropic	  side	  effects	  and	   would	   be	   of	   therapeutic	   value	   in	   pain	   relief,	   inflammation,	   osteoporosis,	   and	   in	   the	  treatment	  of	  cancer	  and	  mental	  disorder	  such	  as	  Alzheimer's	  disease.	  These	  ligands	  serve	  as	  novel	  templates	  for	  the	  development	  of	  selective	  CB2	  receptor	  agonists.	  A	   series	   of	   biarylpyrazolyloxadiazole	   derivatives	   were	   investigated	   as	   antagonists	   to	  cannabinoid	  CB1	  and	  CB2	  receptors.	  The	  cyclization	  of	   substituted	  1H-­‐pyrazole-­‐3-­‐carbonyl-­‐hydrazines	  was	  described	  by	  Lee	  et	  al.68	  under	  MW.	  The	  reaction	  was	  performed	  at	  140°C	  in	  the	  presence	  of	  a	  dehydrating	  agent	  (i.e.,	  methyl	  N-­‐(triethylammoniumsulfonyl)-­‐	  carbamate,	  Burgess	  reagent)	  in	  15	  min	  of	  irradiation	  in	  a	  closed	  vessel	  (Biotage	  MW	  reactor)	  to	  give	  1,3,4-­‐oxadiazole	  62	  (Scheme	  43).	  
	  	  The	   study	   was	   aimed	   to	   validate	   the	   hypothesis	   that	   1,3,4-­‐oxadiazole	   could	   act	   as	   a	  bioisostere	   for	   the	   amide	   moiety	   because	   several	   compounds	   in	   this	   series	   exceeded	   the	  potency	  of	  known	  CB1	  antagonists	  that	  bear	  an	  amide	  moiety.	  This	  class	  of	  compounds	  shows	  promising	  therapeutic	  potential	  as	  a	  CB1	  receptor	  antagonist	  for	  the	  treatment	  of	  obesity.	  Wu	   et	   al.69	   were	   interested	   in	   the	   identification	   of	   new	   antagonists	   for	   the	   NPY5	  (Neuropeptide	  Y	  5)	  receptor,	  which	   is	   involved	   in	  many	  different	  biological	   functions	  of	   the	  central	   and	   peripheral	   nervous	   systems.	   For	   example	   NPY5	   antagonists	   may	   be	   useful	   in	  controlling	  food	  intake	  and	  treating	  obesity.	  Moderately	  potent	  NPY5	  antagonists	  contain	  the	  benzothiazepinoneglycinamide	   scaffold,	   but	   these	   molecules	   have	   little	   stability	   and	   poor	  pharmacokinetic	  properties.	  The	  authors	  investigated	  a	  possible	  optimization	  of	  this	  scaffold	  in	  order	  to	  overcome	  these	  problems.	  They	  synthesised	  benzothiazepines	  using	  MW-­‐assisted	  cyclisation.	  Specifically,	  the	  condensation	  of	  2-­‐aminothiophenol	  with	  methacrylate	  derivatives	  afforded	  benzothiazepinones	  which	  were	  reduced	  to	  benzothiazepines	  63	  (Scheme	  44).	  	  
	  	  Further	  functionalization	  of	  this	  moiety	  led	  to	  a	  series	  of	  compounds	  that	  have	  proven	  to	  be	  good	   NPY5	   antagonists.	   The	   authors	   also	   reported	   a	   deep	   SAR	   study	   into	   their	   structure–activity	  relationship.	  The	   benzodiazepine	   nucleus	   is	   perhaps	   better	   known.	   It	   is	   an	   important	   pharmacophore	  scaffold,	   which	   has	   a	   wide	   range	   of	   therapeutic	   and	   pharmacological	   properties.	   Many	  members	   of	   the	   benzodiazepine	   family	   are	   currently	   widely	   used	   as	   antianxiety,	  antidepressant,	  sedative,	  hypnotic,	  tranquilizing,	  anticonvulsant,	  antihistaminic,	  analgesic	  and	  anti-­‐inflammatory	   agents.	   Because	   of	   their	   wide	   range	   of	   biological	   applications,	   the	  development	   of	   mild,	   efficient	   and	   environmentally	   friendly	   protocols	   continues	   to	   be	   a	  challenging	  endeavour	   for	  organic	  chemists.	  As	  a	  result,	   considerable	  attention	  has	  recently	  been	  drawn	  to	  new	  improved	  methods	  for	  the	  preparation	  of	  1,5-­‐benzodiazepines,	  including	  one-­‐pot	   three-­‐component	  reactions.	  Neochoritis	  et	  al.70	  described	  a	  comparative	  study	   into	  the	   synthesis	   of	   6-­‐hydroxy-­‐2,3-­‐dihydro-­‐1H-­‐1,5-­‐	   benzodiazepines	   and	   6-­‐amino-­‐2,3-­‐dihydro-­‐1,5-­‐benzoxazepines	  via	  the	  condensation	  of	  ketones	  with	  2,3-­‐diaminophenol	  in	  a	  one-­‐pot	  MW	  assisted	  (Biotage	  Initiator	  2.0)	  acid	  catalysed	  reaction	  without	  a	  solvent	  (Scheme	  45).	  
	  From	   Scheme	   45	   and	  Table	   1	   it	   can	   be	  concluded	   that	   the	  presence	   of	   electron-­‐withdrawing	  substituents	   in	   the	  acetophenone	   moiety	  stabilises	   the	   initially	  formed	   1,5-­‐benzoxazepines	   64a–h	  and	   consequently	  facilitates	  their	  isolation.	  On	   the	   other	   hand,	   the	  presence	   of	   electron-­‐releasing	   substituents	  means	   that	   the	   electron	  rich	   oxygen	   is	   easily	  protonated,	   resulting	   in	  the	   spontaneous	  transformation	   of	  benzoxazepines	   64a–h	  into	   benzodiazepines	  65a–h.	  	  The	  synthesis	  of	  6-­‐hydroxybenzodiazepines	  was	  investigated	  and	  compared	  to	  that	  of	  their	  6-­‐aminobenzoxazepine	   counterparts.	   It	   was	   established	   that	   benzoxazepines	   are	   the	   kinetic	  products,	  whereas	  benzodiazepines	  are	  the	  thermodynamic	  ones.	  Several	   new	   benzodiazepines	   and	   benzoxazepines	   have	   been	   synthesised	   with	   the	   aim	   of	  studying	  their	  antioxidant	  and	  anti-­‐inflammatory	  activity.	  Novel	  compounds	  were	  tested	  with	  regard	  to	  their	  antioxidant	  ability	  as	  well	  as	  their	  potent	  lipid	  peroxidation	  (LPO)	  inhibitory	  activity.	  In	  terms	  of	  biological	  activity,	  the	  most	  interesting	  antioxidant	  derivatives	  were	  those	  with	  the	  benzoxazepine	  moiety	  and	  the	  amino	  group	  substituent.	  Nascimento-­‐Ju	  ́nior	   et	   al.71	   used	   MW	   irradiation	   under	   solvent-­‐free	   conditions	   to	  dramatically	  improve	  the	  process	  for	  obtaining	  new	  heterocyclic	  scaffolds,	  exploiting	  the	  aza-­‐Diels–Alder	   reaction	   as	   the	   key-­‐step.	   The	   classic	   synthesis	   of	   heterocyclic	   derivatives	   that	  include	   the	  pyrazolo[3,4-­‐b]pyrrolo[3,4-­‐d]	  pyridine	  scaffold	  gave	  poor	  yields	   (20–35%)	  even	  after	  48	  h	  heating	  in	  either	  AcOH	  or	  DMSO	  as	  a	  solvent.	  Easier	  access	  to	  these	  structures	  was	  achieved	   via	  MW-­‐assisted	   hetero	  Diels–Alder	   reactions,	   improving	   yields	   and	   cutting	   down	  reaction	   times	   (Scheme	   46).	   The	  method	   required	   irradiation	   at	   80°C	   for	   1.5	   h	   in	   an	   open	  vessel	  (80	  W	  in	  Discovery	  -­‐	  CEM).	  
	  
	  
	  	  Compounds	  containing	  the	  pyrazolo[3,4-­‐b]pyrrolo[3,4-­‐d]	  pyridine	  scaffold	  were	  described	  as	  displaying	   CNS	   action	   as	   muscarinic	   M1	   receptor	   agonists.	   Although	   these	   heterotricyclic	  compounds	  presented	  a	  remarkable	  neuroactive	  profile	   (as	  sedatives	  and	  analgesic	  agents),	  further	   preclinical	   studies	   were	   strongly	   limited	   by	   the	   critical	   synthesis.	   The	   sedation	  produced	  by	  derivatives	  (66a–f	  and	  67a–f)	  was	  investigated	  using	  locomotor	  activity	  tests	  in	  mice.	   Taken	   together,	   results	   showed	   that	   almost	   all	   of	   the	   N-­‐methyl	   pyrazole	   derivatives	  (group	  A)	  are	  crucial	  in	  promoting	  the	  sedative	  effect.	  Zhang	   et	   al.72	   prepared	   2-­‐aminothiazole	   analogues	   in	   which	   the	   application	   of	   MW	  technology	   was	   used	   for	   the	   cyclisation	   reaction.	   The	   synthesis	   of	   4,5-­‐substituted-­‐2-­‐aminothiazole	  was	  in	  accordance	  with	  a	  published	  procedure,	  but	  improved	  by	  a	  MW-­‐assisted	  cyclisation	  step	  (household	  oven,	  power	  650	  W),	  which	  gave	  results	  after	  a	  few	  minutes	  vs.	  12	  h	  under	  conven-­‐	  tional	  thermal	  heating	  (Scheme	  47).	  
	  	  This	   heterocycle	   is	   an	   attractive	   lead	   for	   the	   synthesis	   of	   new	   agents	   that	   can	   inhibit	  poly(ADP-­‐ribose)	  polymerases	  (PARPs).	  PARPs	   are	   known	   as	   nuclear	   enzymes	   that	   catalyse	   the	   poly-­‐(ADP-­‐ribosyl)ation	   of	   DNA-­‐binding	   proteins,	   regulate	   immediate	   cellular	   response	   to	   DNA	   damage	   and	   facilitate	   DNA	  repair.	  Because	  of	   its	  role	   in	  many	  common	  pathologies	  of	  various	  central	  nervous	  system	  diseases	  such	   as	   cell	   death,	   inflammatory	   responses,	   excitotoxicity	   and	   mitochondrial	   functional	  disorder,	   PARP-­‐1	   has	   attracted	   more	   and	   more	   attention	   as	   a	   suitable	   target	   for	  
neuroprotective	  agents.	  The	  2-­‐aminothiazole	   framework	  was	  singled	  out	  as	  a	  novel	  PARP-­‐1	  inhibitor	  scaffold	  via	  computer-­‐aided	  drug	  design.	  Andersson	  et	  al.73	  employed	  the	  olefin	  ring-­‐closing	  metathesis	  reaction	  (RCM)	  to	  perform	  a	  macrocyclisation	  and	  obtain	  a	  substituted	  dioxo-­‐1,4-­‐diazacyclotetradec-­‐7-­‐ene,	  compound	  71.	  Compounds	  were	   prepared	   by	  manual	   SPPS	   using	   the	   9-­‐fluorenylmethoxycarbonyl	   (Fmoc)	  protection	  strategy,	  followed	  by	  side	  chain	  to	  side	  chain	  cyclisation	  via	  RCM.	  One	   example	   of	   a	   MW-­‐assisted	   reaction	   is	   reported	   in	   Scheme	   48	   (Smith	   Synthesizer	   -­‐	  Biotage).	  
	  	  The	   cyclisation	  was	   performed	   on	   a	   preparative	   scale	   using	   HGII	   (Hoveyda-­‐Grubbs	   second	  generation	   catalyst)	   (0.15	   equiv.)	   at	   150?C	   for	   5	   min	   and	   repeated	   once	   after	   a	   second	  addition	   of	   the	   catalyst.	   This	   reaction	   provided	   potent	   inhibitors	   of	   insulin-­‐regulated	  aminopeptidase	   (IRAP),	   which	   is	   an	   enzyme	   found	   in	   areas	   of	   the	   brain	   associated	   with	  memory	  and	  learning.	  The	  design,	  synthesis	  and	  biochemical	  evaluation	  of	  novel	  13-­‐	  and	  14-­‐membered	   macrocyclic	   tripeptide	   analogues	   of	   Angiotensin	   IV	   were	   presented.	   It	   was	  demonstrated	  that	  the	  replacement	  of	  a	  disulphide	  bridge	  with	  a	  carbon–carbon	  bridge	  in	  the	  N-­‐terminal	   macrocyclic	   part	   was	   well	   tolerated.	   The	   most	   potent,	   selective	   and	   stable	  analogue	  in	  the	  series,	  71	  (Ki	  1⁄4	  4.1	  nM),	  serves	  as	  a	  starting	  point	  for	  further	  optimisation.	  	  
6	  Anticancer	  activity	  The	   burden	   of	   cancer	   continues	   to	   increase	   on	   a	   global	   scale,	   largely	   because	   of	   world	  population	  growth	  and	  aging,	  along-­‐side	  the	  increasing	  adoption	  of	  cancer-­‐causing	  behaviour	  particularly	  in	  economically	  developing	  countries.	  The	  effectiveness	  of	  chemotherapy	  is	  often	  limited	  by	  its	  toxicity	  to	  other	  tissues	  in	  the	  body.	  Research	  in	  the	  area	  never	  stops	  and	  MW-­‐	  assisted	   synthesis	   may	   help	   find	   greener	   and	   faster	   access	   to	   libraries	   of	   N-­‐heterocycle	  compounds	  to	  be	  screened	  as	  anti-­‐cancer	  drugs.	  Another	   example	   of	   1,3,4-­‐substituted	   oxadiazole	   synthesis	   via	   MW-­‐assisted	   dehydrative	  cyclisation	  using	  the	  Burgess	  reagent	  was	  described	  by	  Rai	  et	  al.74	  (Scheme	  49).	  
	  	  
The	  authors	  were	  interested	  in	  the	  optimization	  of	  apurinic/	  apyrimidinic	  (AP)	  endonuclease	  1	  (APE1)	   inhibitors	  containing	   this	  N-­‐heterocycle.	  APE1	   is	  an	  attractive	   target	   in	  anticancer	  treatments	  and	  is	  the	  main	  enzyme	  responsible	  for	  the	  removal	  of	  a	  basic	  (or	  AP)	  sites	  in	  DNA	  in	  mammals.	   Indeed,	  APE1	   is	   normally	   activated	   so	   it	   can	   cause	  DNA	  damage,	   therefore	   its	  inhibition	  may	  improve	  the	  activity	  of	  anticancer	  drugs	  that	  interact	  with	  DNA.	  MW-­‐assisted	  syntheses	  of	  compound	  72	  and	  many	  other	  analogues	  have	  led	  to	  both	  an	  improvement	  in	  the	  potency	  of	  the	  initial	   lead	  compound	  and	  the	  discovery	  of	  new	  APE1	  inhibitors.	  These	  small	  molecules	   exhibit	   activity	   against	   the	   purified	   APE1	   enzyme.	   Moreover,	   this	   class	   of	  compounds	  possesses	  a	  generally	  favourable	  in	  vitro	  ADME	  profile,	  along	  with	  good	  exposure	  levels	  in	  plasma	  and	  the	  brain.	  1,3,4-­‐Oxadiazole	   derivatives	   were	   also	   obtained	   by	   Tong	   et	   al.75	   from	   the	   corresponding	  benzohydrazide	  via	  condensation	  with	  methyl	  orthoformate	  at	  160°C	  under	  MW	  irradiation	  for	  30	  min	  (Scheme	  50)	  (Discover	  -­‐	  CEM	  MW	  reactor).	  
	  	  More	   than	   a	   decade	   ago,	   scientists	   from	   the	   University	   of	   Newcastle	   identified	   a	   class	   of	  benzoxazole-­‐4-­‐carboxamide	   compounds	   as	   weak	   poly(ADP-­‐ribose)	   polymerase	   (PARP)	  inhibitors.76	  The	  authors	  disclosed	  the	  development	  of	  a	  distinct	  class	  of	  inhibitors	  that	  had	  unsaturated	   heterocycles	   attached	   to	   the	   benzimidazole	   core.	   PARP-­‐1	   is	   a	   nuclear	   enzyme	  that	  is	  part	  of	  a	  larger	  family	  of	  PARP	  enzymes.	  DNA	  damage	  activates	  PARP-­‐1,	  causing	  it	  to	  cleave	   its	  substrate	  nicotinamide	  adenine	  dinucleotide	  (NAD)	  and	  transfer	  ADP-­‐ribose	  units	  to	  nuclear	  target	  proteins	  that	  can	  facilitate	  DNA	  repair.	  This	  mechanism	  allows	  cancer	  cells	  to	   escape	   apoptosis	   induced	   by	   DNA	   damaging	   treatments	   such	   as	   chemotherapy	   and	  radiation	  and	  enables	  cancer	  cells	  to	  repair	  the	  drug-­‐induced	  DNA	  lesions.	  For	  this	  reason,	  the	  inhibition	  of	  PARP-­‐1	  has	  become	  an	  attractive	  strategy	   for	  anticancer	   therapy.	  A	  number	  of	  these	   inhibitors	  demonstrated	  high	  potency	   in	  both	   enzymatic	   and	   cellular	   assays;	   some	  of	  them	   also	   exhibited	   good	   pharmacokinetic	   properties	   and	   potent	   oral	   in	   vivo	   efficacy	   in	  potentiating	   the	   cytotoxic	   agent	  Temozolomide	   (TMZ)	   in	   a	  mouse	   xenograft	  model.	   Results	  show	   that	   the	   installation	   of	   an	   unsaturated	   heterocycle	   on	   the	   2-­‐phenyl	   group	   of	   the	  benzimidazole	   core	   proved	   to	   be	   another	   viable	   strategy	   for	   developing	   potent	   and	   orally	  efficacious	  PARP-­‐1	  inhibitors.	  Lavieri	   et	   al.77	   focused	   on	   the	   functionalisation	   of	   the	   1,3,8-­‐	   triazaspiro[4,5]decan-­‐4-­‐one	  scaffold	  with	  various	  halogens.	  In	  these	  syntheses,	  the	  closing	  of	  the	  spirocycli	  five-­‐membered	  ring	   meant	   forcing	   MW	   conditions	   at	   150?C	   for	   15	   min	   in	   AcOH	   (single	   mode	   Biotage	  Initiator-­‐60),	  followed	  by	  reduction	  to	  provide	  the	  desired	  product	  (Scheme	  51).	  
	  	  A	   compound	   library	   was	   prepared,	   using	   this	   method,	   and	   tested	   for	   the	   PLD1	   inhibiting	  activity.	  PLD	  (phospholipase	  D)	  catalyses	  the	  hydrolysis	  of	  phosphatidylcholine	  into	  the	  lipid	  second	   messenger	   phosphatidic	   acid	   and	   choline.	   Evidence	   from	   genetic	   and	   biochemical	  experiments	  indicates	  that	  PLD	  is	  an	  attractive	  target	  for	  cancer	  therapy.	  The	   development	   of	   isoform-­‐selective	   PLD	   inhibitors,	   specifically	   PLD2-­‐selective	   inhibitors,	  may	  lead	  to	  a	  new	  class	  of	  cancer	  therapeutics.	  The	  authors	  reported	  the	  results	  of	  a	  matrix	  library	   approach	   to	   increasing	   PLD2	   potency	   and	   selectivity	   within	   the	   1,3,8-­‐triazaspiro-­‐[4,5]decan-­‐4-­‐one	  series.	  All	  library	  members	  were	  evaluated	  for	  their	  ability	  to	  inhibit	  PLD1	  and	  PLD2	  in	  cellular	  and	  biochemical	  assays	  with	  recombinant	  PLD1	  and	  PLD2	  enzymes.	  The	  most	  potent	  (PLD2	  IC50	  1⁄4	  20	  nM)	  and	  selective	  (75-­‐fold	  versus	  PLD1)	  PLD2	  inhibitor	  was	  compound	  75.	  Quinols	  (4-­‐hydroxycyclohexa-­‐2,5-­‐dien-­‐1-­‐ones)	  substituted	  with	  a	  heterocyclic	  fragment	  at	  the	  4-­‐position	   constitute	   a	   new	   pharmacophore	   in	   anticancer	   drug	   research.	   Classic	   quinol	  synthetic	  methods,	  however,	  have	  given	  variable	  yields,	  generally	  less	  than	  40%	  and	  in	  some	  cases	   reactions	  have	   failed	   completely.	  Alkynyl-­‐substituted	  quinol	  derivatives	   react	  with	  N-­‐arylsulfonyl-­‐2-­‐iodoanilines	  under	  Sonogashira	  conditions	  as	  described	  by	  McCarroll	  et	  al.78	  Best	   conditions	   were	   found	   to	   be	   MW	   irradiation	   of	   the	   homogeneous	   catalyst	   tetrakis-­‐	  (triphenylphosphine)palladium	   and	   copper	   iodide	   in	   a	   diisopropylamine/aqueous	   DMAC	  medium	  at	  100°C.	  The	  corresponding	  indoles	  were	  obtained	  in	  only	  10	  min	  and,	  therefore,	  it	  has	   been	   shown	   that	   MW-­‐assisted	   Sonogashira	   coupling	   chemistry	   can	   be	   employed	   to	  construct	  a	  new	  series	  of	  indolylquinols	  (Scheme	  52).	  
	  	  These	  derivatives	  were	  tested	  and	  showed	  selective	  in	  vitro	  activity	  especially	  against	  cancer	  cells	  of	  colon,	  renal,	  and	  melanoma	  origin.	  Hajbi	   et	   al.79	  prepared	  new	   furocarbazoles	   from	   formylindoles	  and	  various	  benzaldehydes.	  Their	   straightforward	  and	  efficient	   synthesis	  gave	  access	   to	  esters	  which	  were	   then	   readily	  used	  in	  a	  6p-­‐electrocyclisation/aromatisation	  reaction.	  The	  one-­‐pot	  Diels–Alder	  reaction	  was	  efficiently	  performed	  under	  MW	  irradiation	  (Biotage	  Initiator)	  (Scheme	  53).	  
	  After	   furocarbazole	  deprotection	   and	   methyl	   ether	  cleavage,	   the	   compounds	  obtained	  were	  evaluated	  for	  the	  DNA	   top-­‐	   oisomerase	   II	  inhibitor	   activity,	   although	   few	  promising	   candidates	   were	  discovered.	   This	   is	   possibly	  because	   they	   make	   use	   of	  different	   mode	   of	   action	   than	  etoposide,	   which	   is	   frequently	  prescribed	   in	   oncology	   and	   for	  which	   toxicities	   and	   resistance	  are	  known.	  Rescifina	   et	   al.80	   reported	   the	  synthesis	   of	   isoxazolidinyl	  polycyclic	   aromatic	  hydrocarbons	   (isoxazolidinyl-­‐PAHs),	  featuring	  the	  presence	  of	  an	  isoxazolidine	  ring	  on	  an	  aromatic	  planar	  system	  made	  up	  of	   an	   anthracene,	   a	   phenanthrene	   and	   a	   pyrene	   moiety.	   A	   marked	   improvement	   in	   the	  cycloaddition	  was	  obtained	  under	  MW	  irradiation,	  as	  in	  the	  case	  of	  nitrones,	  using	  a	  Discover	  reactor	  -­‐	  CEM	  (Scheme	  54,	  Table	  2).	  
	  	  
	  	  These	  isoxazolidinyl-­‐PAHs	  were	  the	  first	  members	  of	  a	  new	  series	  of	  potential,	  non-­‐ionic	  DNA	  intercalators.	  Research	  into	  the	  development	  of	  non-­‐peptide-­‐based	  DNA	  interactive	  drugs	  has	  been	  intense,	  since	   such	   agents	   offer	   the	   potential	   to	   interact	   with	   their	   intended	   target	   without	   falling	  hostage	   to	   cellular	   peptidases.	   Of	   the	   established	   drug-­‐DNA	   associative	   methods	   available,	  intercalation	  is	  one	  of	  the	  most	  predictable,	  and	  a	  variety	  of	  natural	  and	  synthetic	  agents	  that	  work	  using	  this	  strategy	  show	  excellent	  antitumour	  activity.	  
	  
A	   new	   class	   of	   potential	   DNA	   intercalation	   agents,	   the	   isoxazolidinyl-­‐PAHs,	   has	   been	  synthesised	   according	   to	   the	  1,3-­‐	   dipolar	   cycloaddition	  methodology	   and	  promoted	  by	  MW	  irra-­‐	  diation.	  A	  systematic	  investigation	  into	  structural	  variations	  of	  the	  isoxazolidine	  nucleus	  was	  carried	  out	  to	  gain	  further	  details	  as	  to	  this	  template's	  potential	  as	  an	  antitumour	  agent.	  New	   benzimidazole-­‐4,7-­‐diones,	   substituted	   at	   the	   2-­‐position,	   were	   synthesised	   via	   a	   MW-­‐assisted	  reaction	  (multimode	  ETHOS,	  Milestone)	  by	  Gellis	  et	  al.81	  (Scheme	  55).	  A	   series	   of	   variously	   substituted	   benzimidazole-­‐4,7-­‐diones	   were	   synthesised	   from	   this	  intermediate	   and	   tested	   for	   their	   antitumour	   activity.	   Substituents	  with	  different	   electronic	  and	   solubility	   characteristics	   were	   selected,	   while	   others	   were	   chosen	   for	   their	   alkylating	  properties.	   The	   aim	   here	  was	   to	   investigate	   the	   effects	   of	   substituents	   at	   the	   2-­‐,	   5-­‐	   and	   6-­‐position.	  Their	   cytotoxicity	  was	  evaluated	  on	  colon,	  breast	  and	   lung	  cancer	  cell	   lines.	  One	  compound	  was	  shown	  to	  possess	  excellent	  cytotoxicity	  which	  was	  comparable	  to	  that	  of	  mitomycin	  C.	  A	   series	   of	   2,4,5-­‐trisubstituted	   oxazole	   derivatives	   that	   contain	   a	   heterocyclic	  moiety	  were	  designed	  and	  synthesised	  by	  Liu	  et	  al.82	  MW	  irradiation	  promoted	  the	  rapid	  O,N-­‐acylation–	  cyclodehydration	  cascade	  reaction	  between	  oximes	  and	  acid	  chloride,	  and	  twenty	  novel	  2,4,5-­‐trisubstituted	   oxazole	   derivatives	   containing	   the	   heterocycle	   moiety	   were	   synthesised	  (Scheme	  56).	  
	  In	   addition	   to	   much	   faster	   conversion,	   the	   major	   advantage	   of	   MW	   irradiation	   was	   a	  significantly	  increased	  yield,	  as	  can	  be	  seen	  in	  Table	  3.	  
	  	  
Oxazoles	   are	   one	   of	   the	   key	   building	   elements	   of	   natural	   products.	   The	   oxazole	   ring	   is	  endowed	  with	  a	  number	  of	  interesting	  effects	  that	  set	  it	  apart	  from	  the	  numerous	  heterocyclic	  moieties	   of	   biological	   and	   pharmacological	   interest,	   one	   such	   effect	   is	   the	   antiproliferative	  activity.	  Parekh	  et	  al.83	  have	  synthesised	  some	  novel	  benzofuran	  functionalised	  pyrazole	  derivatives	  using	  MW	  irradiation	  (Scheme	  57).	  
	  	  They	   demonstrated	   some	   easy	   and	   fast	   benzofuran-­‐2-­‐yl-­‐	   (4,5-­‐dihydro-­‐3,5-­‐substituted	  diphenylpyrazol-­‐1-­‐yl)methanone	   syntheses	   under	   MW	   irradiation.	   All	   the	   synthesised	  compounds	  were	  examined	  for	  the	  antiproliferative	  activity.	  One	  of	  the	  main	  problems	  currently	  facing	  the	  treatment	  of	  human	  neoplastic	  diseases	  is	  the	  phenomenon	   of	   multidrug	   resistance	   (MDR)	   to	   the	   many	   anticancer	   agents	   used	   in	  chemotherapy.	   Therefore,	   these	   compounds	   were	   also	   tested	   for	   their	   ability	   to	   reverse	  multidrug	   resistance	   in	   human	   MDR1-­‐	   gene	   transfected	   mouse	   lymphoma	   cells	   in	   vitro.	  Compounds	  82a-­‐x	  were	  found	  to	  have	  a	  high	  inhibitory	  effect	  on	  the	  MDR	  reversal	  activity.	  Shi	   et	   al.84	   carried	   out	   the	   design	   and	   diversity-­‐oriented	   synthesis	   of	   novel	   1,4-­‐thiazepine	  derivatives	  which	  were	  embedded	  with	  carbazole,	  pyrazole	  and	  isoxazole	  motifs	  in	  a	  solvent-­‐free	   MW-­‐assisted	   three-­‐component	   reaction	   (10	   min	   at	   120°C,	   with	   a	   monomodal	   Emrys	  Creator	  –	  Biotage)	  (Scheme	  58).	  
	  	  A	  number	  of	  heteroaromatic	  amines	  (containing	  carbazole,	  pyrazole	  and	  isoxazole	  skeletons)	  and	   various	   aldehydes	   (including	   electron	   rich	   and	   poor	   aromatic	   aldehydes	   and	  heteroaromatic	  aldehydes)	  were	  used	  to	  obtain	  target	  molecules	  in	  which	  each	  included	  one	  of	   the	   bioactive	   1,4-­‐thiazepine	   and	   carbazole,	   pyrazole	   and	   isoxazole	   units.	   The	   protocol	   is	  
applicable	  to	  a	  wide	  range	  of	  aldehydes	  and	  heteroaromatic	  amines	  and	  can	  provide	  a	  library	  of	  novel	  1,4-­‐thiazepine	  derivatives	  83	  in	  high	  yields	  (88–94%)	  and	  in	  short	  reaction	  times	  (8–10	  min).	  These	  new	  1,4-­‐thiazepine	  derivatives	  underwent	  cytotoxicity	  tests	  in	  the	  carcinoma	  cell	   line	  HCT	  116	  (ATTC	  CCL	  247)	  and	  mice	  lymphocytes.	  They	  exhibited	  high	  selective	  cytotoxicity	  to	  HCT	  116	  cells.	  These	  results	  suggest	  that	  the	  1,4-­‐thiazepine	  derivatives	  83	  exhibit	  remarkable	  selective	  cytotoxicity	  to	  this	  carcinoma	  cell	  line.	  This	  study	  has	  achieved	  a	  green	  and	  easy	  route	  to	  1,4-­‐thiazepine	  derivatives,	  which	   include	  bioactive	   heterocyclic	   skeletons,	   which	   may	   well	   find	   pharmaceutical	   applications	   after	  further	  investigation.	  Shi	   et	   al.85	   reported	   an	   efficient	   synthesis	   of	   new	   4-­‐aza-­‐podophyllotoxin	   analogues	   that	  contain	   thiazole	   skeletons	  84	  via	  MW-­‐assisted	   three-­‐component	   reactions	   (in	  a	  monomodal	  Emrys	  Creator	  –	  Biotage)	  of	  aromatic	  aldehydes,	  tetronic	  acid	  and	  2-­‐methylbenzo[d]thiazol-­‐5-­‐amine	  (Scheme	  59).	  
	  	  A	   possible	   reaction	   mechanism	   may	   involve	   the	   Knoevenagel	   condensation	   between	  aldehydes	   and	   tetronic	   acid	   in	   the	   initial	   step.	   Next,	   the	   Michael	   addition	   of	   2-­‐methylbenzo[d]thiazol-­‐5-­‐amine	   to	   the	   first	   adduct	   may	   provide	   another	   open-­‐chain	  intermediate,	  which	  may	   give	   rise	   to	   the	   final	   products	   84	   upon	   intramolecular	   cyclisation	  and	  dehydration.	  Under	   these	   optimised	   conditions,	   a	   variety	   of	   substituted	   aromatic	   and	   heteroaromatic	  aldehydes	  were	  used	  as	  reactants	  (Table	  4).	  Both	  aromatic	  aldehydes	  bearing	  either	  electron-­‐	  donating	  groups	  (such	  as	  alkoxy	  and	  methyl)	  or	  electron-­‐withdrawing	  groups	  (such	  as	  nitro	  or	   halide)	   and	   heterocyclic	   thiophene-­‐2-­‐carbaldehyde	   (84l)	   showed	   high	   reactivity	   and	  afforded	  good	  yields	  of	  4-­‐aza-­‐podophyllotoxin	  analogues	  84.	  	  
	  	  
In	   vitro	   cytotoxicity	   tests	   on	   the	   malignant	   melanin	   carcinoma	   cell	   line	   M14,	   mammary	  carcinoma	  cell	   line	  MCF7	  and	  colon	  carcinoma	  cell	   line	  SW1116	  showed	  moderate	  to	  strong	  cytotoxicity	   to	   the	   three	   carcinoma	   cell	   lines,	   making	   these	   promising	   antitumour	   drug	  candidates	  that,	  however,	  require	  further	  structural	  modification	  and	  biological	  investigation.	  This	   approach	   not	   only	   provides	   a	   valuable	   tool	   in	   the	   design	   and	   synthesis	   of	   new	   4-­‐aza-­‐podophyllotoxin	  analogues,	  but	  it	  also	  has	  the	  advantages	  of	  atom-­‐economy,	  environmental-­‐	  friendliness,	  good	  yields	  and	  operational	  simplicity.	  	  
7	  Other	  activities	  There	  are	  a	  number	  of	  methodologies	  that	  allow	  access	  to	  the	  2-­‐	  aryl	  benzoxazole	  core.	  The	  most	  generally	  applicable	  synthetic	  route	  uses	  a	  cyclocondensation	  between	  an	  aminophenol	  and	   either	   a	   carboxylic	   acid,	   using	   polyphosphoric	   acid	   (PPA),	   or	   an	   acid	   chloride.	   While	  thermal	   activation	   of	   the	   reaction	   has	   often	   been	   the	   heating	   method	   of	   choice,	   MW	  irradiation	  has	  also	  proven	   to	  be	  an	  extremely	  effective	  accelerant,	  particularly	   in	  reactions	  that	  use	  an	  acid	  chloride.	  Chancellor	   et	   al.86	  have	  published	   the	   synthesis	   of	   a	   series	   of	   novel	   2-­‐arylbenzoxazoles	   85	  and	  86.	  In	  some	  cases,	  the	  ben-­‐	  zoxazole	  core	  was	  obtained	  via	  MW	  irradiation	  of	  the	  corre-­‐	  sponding	   aminophenolic	   compound	   and	   the	   arylcarboxylic	   acid	   or	   chloride	   (Scheme	   60).	  (Initiator	  -­‐	  Biotage	  or	  Explorer	  -­‐	  CEM).	  
	  	  Benzoxazole	  was	   identified	  as	  a	  small	  molecule	  up-­‐regulator	  of	  utrophin,	  a	  protein	  which	   is	  the	   autosomal	   paralogue	   of	   dystrophin.	   Up-­‐regulation	   of	   utrophin	   has	   been	   proposed	   as	   a	  potential	   treatment	   paradigm	   for	  Duchenne	  muscular	   dystrophy	   (DMD),	   the	  most	   common	  form	   of	   muscular	   dystrophy	   in	   children	   and	   which	   has	   been	   linked	   to	   a	   mutation	   in	   the	  dystrophin	  gene.	  A	  series	  of	  novel	  2-­‐arylbenzoxazoles	  was	  identified	  by	  the	  authors	  as	  potent	  up-­‐regulators	  of	  utrophin	   production,	   as	   assessed	   by	   an	   H2K	   cell-­‐based	   assay	   with	   a	   luciferase	   reporter	  readout.	  The	  most	  active	  examples	  have	  an	  in	  vitro	  potency	  of	  less	  than	  1	  mM	  and	  give	  in	  vitro	  and	   in	   vivo	   ADME	   profiles	   which	   warrant	   further	   investigation.	   Lead	   optimisation	   studies	  caused	  2-­‐arylbenzoxazolic	  derivatives	  to	  be	  identified	  as	  molecules	  for	  further	  investigation.	  	  
8	  Conclusions	  The	  use	  of	  MW	  irradiation	  in	  the	  preparation	  of	  heterocycle	  libraries	  has	  become	  increasingly	  popular	   in	   the	   pharmaceutical	   and	   academic	   fields.	   Of	   the	  many	   enabling	   technologies	   for	  drug	  discovery	  and	  development,	  MW	  irradiation	  has	  doubtlessly	  given	  the	  most	  impressive	  contribution.	  By	  taking	  advantage	  of	  this	  efficient	  energy	  source,	  compound	  libraries	  for	  lead	  generation	   and	   optimisation	   have	   been	   assembled	   in	   a	   fraction	   of	   the	   time	   required	   by	  classical	  thermal	  methods	  and	  often	  in	  much	  higher	  yields.	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